- Published on
Infectious Disease -Bronchiolitis
BASICS DESCRIPTION: Acute bronchiolitis is a lower respiratory tract illness that is caused by an inflammatory blockage of the small bronchioles. Although bacterial infections can also cause bronchiolitis, viral infections are the most common cause.
Bronchiolitis is an inflammatory condition that primarily affects the terminal and respiratory bronchioles, and may, in certain instances, expand to the neighboring alveolar ducts and alveolar spaces.
EPIDEMIOLOGY
Occurrence
The prevalence of bronchiolitis might reach 11 cases per 100 children annually during both the first and second six months of life. During the initial six months of life, six infants per 1,000 are admitted to the hospital annually in the US due to bronchiolitis. The management of hospitalized babies with bronchiolitis is estimated to expenditures may reach $300 million annually.
Each year in the United States, there are a minimum of 675,000 ambulatory children and 75,000 hospitalized children under the age of 2 diagnosed with bronchiolitis.
In 1995, bronchiolitis represented 17% of all baby hospitalizations in New York State, equating to 9 admissions per 1000 child-years.
Bronchiolitis is the predominant cause of infant hospitalization. It exhibits a seasonal pattern, with peak incidence occurring throughout the winter to spring months.
FACTORS OF RISK
Bronchiolitis often manifests within the initial two years of life, with a peak incidence around six months of age.
Bronchiolitis predominantly affects male infants aged 3 to 6 months who are not breastfed and reside in overcrowded environments.
| Infants exposed to cigarette smoke have an increased likelihood of developing bronchiolitis. • Established etiologies of bronchiolitis encompass inhalation of toxic fumes, tobacco smoke, mineral dust, penicillamine, collagen vascular disorders, and infections. Bone marrow, heart-lung, and lung transplantation have been linked to this condition.
• Prematurity (gestational age less than 37 weeks) • Reduced birth weight • Age under 6–12 weeks • Chronic respiratory illness
• Hemodynamically relevant congenital cardiac malformation • Immunodeficiency • Neurological disorder
• Congenital or anatomical anomalies of the airways
• Passive smoking • Household overcrowding • Childcare participation • Elevated altitude
PATHOPHYSIOLOGY
Viruses infiltrate the bronchiolar epithelial cells, inducing direct injury and leading to inflammation of the small bronchi and bronchioles. Edema, abundant mucus, and desquamated epithelial cells result in the blockage of small airways and atelectasis.
ETIOLOGY • Bronchiolitis is predominantly attributed to the respiratory syncytial virus, accounting for over 50% of cases.
• Additional viruses, including parainfluenza, influenza, rhinovirus, rubeola, mumps, parvovirus, and enterovirus,
Coronavirus, coxsackievirus, human metapneumovirus, and varicella zoster are sometimes isolated.
• In adults, sporadic instances of bronchiolitis induced by viral or bacterial agents (Mycoplasma pneumoniae and Legionella pneumophila) have been documented. • The histopathological characteristics of bronchiolitis encompass inflammatory (cellular) bronchiolitis, constrictive bronchiolitis obliterans, and proliferative bronchiolitis.
FREQUENTLY CO-OCCURRING CONDITIONS
Otitis media
DIAGNOSTIC HISTORY
• Bronchiolitis is defined by the following characteristics: – Air trapping – Nasal congestion
– Cough – Expiratory wheezing – Fever – Grunting – Elevated respiratory effort – Retractions
Tachypnea
Infants with bronchiolitis first have a moderate upper respiratory tract infection characterized by serous nasal discharge and sneezing. The symptoms typically persist for several days and may be associated with a reduced appetite. The fever generally fluctuates between 38.5°C and 39.0°C.
PHYSICAL EXAM • Airflow restriction is a significant clinical finding in patients with constrictive bronchiolitis. Wheezing constitutes Crackles are more prevalent than anticipated, particularly during the initial 15% of inhalation. An examination may indicate a tachypneic newborn frequently exhibiting severe respiratory distress.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• The leukocyte and differential cell counts typically fall within normal parameters. • In extreme instances, viral culture or fast testing for respiratory viruses is warranted.
Chest radiography typically demonstrates lung hyperinflation and an enlarged anteroposterior diameter on the lateral view.
DIFFERENTIAL DIAGNOSIS
• Asthma is the illness most frequently mistaken for acute bronchiolitis. Additional entities to be considered in the differential diagnosis encompass congestive heart failure, tracheal foreign body, pertussis, organophosphate toxicity, and cystic fibrosis.
Bronchopneumonias. • Infants with bronchiolitis experience initial wheezing, in contrast to those with asthma, who exhibit chronic wheezing.
THERAPEUTIC PHARMACEUTICAL
The conventional method for symptomatic management of bronchiolitis has involved supportive care, focusing on oxygen therapy, hydration, and breathing assistance if required.
Infants exhibiting respiratory distress require hospitalization. Patients are often situated in an environment of chilly, humidified oxygen.
Studies assessing the impact of bronchodilators on pulmonary mechanics in babies with bronchiolitis have yielded inconclusive findings. None of these research has assessed the efficacy of nebulized albuterol treatments in patients beyond 4 hours or endorsed the use of bronchodilators to decrease hospitalizations or duration of stay. The American Academy of Pediatrics (AAP) clinical practice recommendation advises against the routine use of bronchodilators in the management of bronchiolitis.
In the outpatient context, short-term efficacy of nebulized beta-adrenergic bronchodilators has been evidenced by enhancements in oxygen levels.
saturation or clinical respiratory assessments.
Complementary and Alternative Therapies
Ribavirin has been utilized for the treatment of respiratory syncytial virus infection since 1985. Its application has been advised for newborns suffering from congestive heart failure and bronchopulmonary dysplasia. Nonetheless, its application continues to be contentious.
CONTINUED MANAGEMENT POST-TREATMENT GUIDELINES
• Certain newborns may advance to respiratory failure and necessitate ventilatory assistance.
A considerable percentage of newborns with bronchiolitis exhibit hyperactive airways in late childhood.
COMPLICATIONS
The case fatality rate is about 1%.
The mortality rate for newborns with high-risk diseases, such as congestive heart failure, immunological deficiency, and cystic fibrosis, is below 3.5%.
BASICS DESCRIPTION: Acute bronchiolitis is a lower respiratory tract illness that is caused by an inflammatory blockage of the small bronchioles. Although bacterial infections can also cause bronchiolitis, viral infections are the most common cause.
Bronchiolitis is an inflammatory condition that primarily affects the terminal and respiratory bronchioles, and may, in certain instances, expand to the neighboring alveolar ducts and alveolar spaces.
EPIDEMIOLOGY
Occurrence
The prevalence of bronchiolitis might reach 11 cases per 100 children annually during both the first and second six months of life. During the initial six months of life, six infants per 1,000 are admitted to the hospital annually in the US due to bronchiolitis. The management of hospitalized babies with bronchiolitis is estimated to expenditures may reach $300 million annually.
Each year in the United States, there are a minimum of 675,000 ambulatory children and 75,000 hospitalized children under the age of 2 diagnosed with bronchiolitis.
In 1995, bronchiolitis represented 17% of all baby hospitalizations in New York State, equating to 9 admissions per 1000 child-years.
Bronchiolitis is the predominant cause of infant hospitalization. It exhibits a seasonal pattern, with peak incidence occurring throughout the winter to spring months.
FACTORS OF RISK
Bronchiolitis often manifests within the initial two years of life, with a peak incidence around six months of age.
Bronchiolitis predominantly affects male infants aged 3 to 6 months who are not breastfed and reside in overcrowded environments.
| Infants exposed to cigarette smoke have an increased likelihood of developing bronchiolitis. • Established etiologies of bronchiolitis encompass inhalation of toxic fumes, tobacco smoke, mineral dust, penicillamine, collagen vascular disorders, and infections. Bone marrow, heart-lung, and lung transplantation have been linked to this condition.
• Prematurity (gestational age less than 37 weeks) • Reduced birth weight • Age under 6–12 weeks • Chronic respiratory illness
• Hemodynamically relevant congenital cardiac malformation • Immunodeficiency • Neurological disorder
• Congenital or anatomical anomalies of the airways
• Passive smoking • Household overcrowding • Childcare participation • Elevated altitude
PATHOPHYSIOLOGY
Viruses infiltrate the bronchiolar epithelial cells, inducing direct injury and leading to inflammation of the small bronchi and bronchioles. Edema, abundant mucus, and desquamated epithelial cells result in the blockage of small airways and atelectasis.
ETIOLOGY • Bronchiolitis is predominantly attributed to the respiratory syncytial virus, accounting for over 50% of cases.
• Additional viruses, including parainfluenza, influenza, rhinovirus, rubeola, mumps, parvovirus, and enterovirus,
Coronavirus, coxsackievirus, human metapneumovirus, and varicella zoster are sometimes isolated.
• In adults, sporadic instances of bronchiolitis induced by viral or bacterial agents (Mycoplasma pneumoniae and Legionella pneumophila) have been documented. • The histopathological characteristics of bronchiolitis encompass inflammatory (cellular) bronchiolitis, constrictive bronchiolitis obliterans, and proliferative bronchiolitis.
FREQUENTLY CO-OCCURRING CONDITIONS
Otitis media
DIAGNOSTIC HISTORY
• Bronchiolitis is defined by the following characteristics: – Air trapping – Nasal congestion
– Cough – Expiratory wheezing – Fever – Grunting – Elevated respiratory effort – Retractions
Tachypnea
Infants with bronchiolitis first have a moderate upper respiratory tract infection characterized by serous nasal discharge and sneezing. The symptoms typically persist for several days and may be associated with a reduced appetite. The fever generally fluctuates between 38.5°C and 39.0°C.
PHYSICAL EXAM • Airflow restriction is a significant clinical finding in patients with constrictive bronchiolitis. Wheezing constitutes Crackles are more prevalent than anticipated, particularly during the initial 15% of inhalation. An examination may indicate a tachypneic newborn frequently exhibiting severe respiratory distress.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• The leukocyte and differential cell counts typically fall within normal parameters. • In extreme instances, viral culture or fast testing for respiratory viruses is warranted.
Chest radiography typically demonstrates lung hyperinflation and an enlarged anteroposterior diameter on the lateral view.
DIFFERENTIAL DIAGNOSIS
• Asthma is the illness most frequently mistaken for acute bronchiolitis. Additional entities to be considered in the differential diagnosis encompass congestive heart failure, tracheal foreign body, pertussis, organophosphate toxicity, and cystic fibrosis.
Bronchopneumonias. • Infants with bronchiolitis experience initial wheezing, in contrast to those with asthma, who exhibit chronic wheezing.
THERAPEUTIC PHARMACEUTICAL
The conventional method for symptomatic management of bronchiolitis has involved supportive care, focusing on oxygen therapy, hydration, and breathing assistance if required.
Infants exhibiting respiratory distress require hospitalization. Patients are often situated in an environment of chilly, humidified oxygen.
Studies assessing the impact of bronchodilators on pulmonary mechanics in babies with bronchiolitis have yielded inconclusive findings. None of these research has assessed the efficacy of nebulized albuterol treatments in patients beyond 4 hours or endorsed the use of bronchodilators to decrease hospitalizations or duration of stay. The American Academy of Pediatrics (AAP) clinical practice recommendation advises against the routine use of bronchodilators in the management of bronchiolitis.
In the outpatient context, short-term efficacy of nebulized beta-adrenergic bronchodilators has been evidenced by enhancements in oxygen levels.
saturation or clinical respiratory assessments.
Complementary and Alternative Therapies
Ribavirin has been utilized for the treatment of respiratory syncytial virus infection since 1985. Its application has been advised for newborns suffering from congestive heart failure and bronchopulmonary dysplasia. Nonetheless, its application continues to be contentious.
CONTINUED MANAGEMENT POST-TREATMENT GUIDELINES
• Certain newborns may advance to respiratory failure and necessitate ventilatory assistance.
A considerable percentage of newborns with bronchiolitis exhibit hyperactive airways in late childhood.
COMPLICATIONS
The case fatality rate is about 1%.
The mortality rate for newborns with high-risk diseases, such as congestive heart failure, immunological deficiency, and cystic fibrosis, is below 3.5%.
- Published on
Infectious Disease - Brain Abscess
BRAIN ABSCESS
FUNDAMENTAL DESCRIPTION
A brain abscess is a localized accumulation of purulent material inside the brain parenchyma resulting from an infectious agent, such as bacteria, fungus, or protozoa. The formation may exhibit a distinct abscess wall or comprise an inflammatory condition (cerebritis).
Epidemiology
Frequency
• Uncommon infection, present in 0.2–1.3% of extensive postmortem studies, and in 1 out of 10,000 hospital admissions. • 25% of brain abscesses occur in pediatric patients. • Median age of infection: 30–45 years.
RISK FACTORS • Sinusitis • Otitis media • Inadequate dental hygiene
• Endocarditis • Bacteremia due to indwelling central lines and intravenous drug usage • Osler–Weber–Rendu syndrome
• Prior brain injury • Immunocompromised state • Cyanotic congenital heart disease
• Intrapulmonary shunting in individuals with arteriovenous malformations
GENERAL PREVENTION • Sinusitis and otitis must be addressed in all patients.
• Proper dental hygiene is essential in the management of apical abscesses, particularly in the upper molars.
PATHOPHYSIOLOGY • Infection may access the brain through the following mechanisms:
- Direct transmission from the sinuses, orbit, dental structures, mastoid, middle ear, and meninges – Post-trauma or neurosurgical intervention – Hematogenous dissemination
ETIOLOGY • The characteristics of the organisms present in the infection frequently
pertains to the method of transmission:
• Middle ear, paranasal sinuses, odontogenic infections - Mixed infections involving anaerobes, microaerophilic streptococci, viridans streptococci, Streptococcus milleri, S. pneumoniae (infrequent), Haemophilus, Fusobacterium, Prevotella melaninogenica, Enterobacteriaceae, Pseudomonas
• Trauma and postoperative considerations: Staphylococcus aureus – Pseudomonas – Additional gram-negative bacteria
– Propionibacterium • Hematogenous:
– Staphylococcus aureus – Salmonella
– Listeria monocytogenes
- Streptococci (notably Streptococcus viridans) Klebsiella pneumoniae
– Escherichia coli, Proteus species – Pseudomonas – Bacteroides species (including Bacteroides fragilis) – Actinomyces – Fungi
• Immunocompromised individuals: – Toxoplasma gondii – Listeria species – Rhodococcus equi
Nocardia asteroides
Aspergillus species, Cryptococcus neoformans, Coccidioides immitis, Candida species, Zygomycetes, Cladosporium trichoides, Curvularia species.
• Immigrants originating from endemic nations: – Taenia solium – Entamoeba histolytica – Schistosoma japonicum – Paragonimus spp.
DIAGNOSIS
The clinical signs are often modest and nonspecific.
• Common symptoms consist of headache lasting less than two weeks (75% of cases), neck stiffness (25%), alterations in mental state, nausea, and vomiting.
• Low-grade fevers may occur in 45–50% of cases.
• Focal neurological abnormalities seen in 50% of cases
• Seizures occur in 25% of cases and may serve as the primary indication for CT screening.
Deficits in the third and sixth cranial nerves, along with papilledema, signify elevated intracranial pressure and cerebral edema. Diagnosis is contingent upon the abscess's location, the causative organism, and any prior conditions that may have contributed to its formation.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• The white blood cell count is high in 60–70% of cases.
• ESR may elevate in 90% of cases.
• Lumbar puncture poses significant risks, particularly in patients exhibiting focal neurological symptoms. If the cerebrospinal fluid mimics that of bacterial meningitis, one may assume a ruptured abscess.
the ventricle
• Microbiological diagnosis • Positive blood cultures • Stereotactic abscess aspiration, cultures, and specific stains • 16S ribosomal sequencing of the aspirate • Serology: Toxoplasmosis, neurocysticercosis
Imaging
CT and MRI are essential diagnostic modalities.
Gadolinium-enhanced MRI provides superior visualization of the brainstem, whereas diffusion-weighted MRI is employed to distinguish between brain abscesses and neoplastic lesions.
• Serial scans must be conducted, particularly when empirical treatment is used.
Ring lesions may endure for a duration of 3 to 4 months, even with appropriate treatment.
Diagnostic Procedures and Additional Methods
• Stereotactic aspiration: The preferred method when the abscess is readily accessible and exceeds 2.5 cm in diameter. • Craniotomy with aspiration: Indicated in regions requiring direct sight of blood vessels when the abscess measures over 2.5 cm in diameter.
DIFFERENTIAL DIAGNOSIS • Epidural and subdural empyema • Septic dural sinus thrombosis • Mycotic aneurysms • Septic cerebral emboli with infarcts • Acute focal necrotizing encephalitis • Metastatic or primary brain tumors • Pyogenic meningitis • Hematoma • Radiation necrosis
ADDITIONAL TREATMENT
Comprehensive Strategies
The antibiotic treatment is contingent upon the probable source of the infection.
• Commence empiric antibiotics promptly following the acquisition of the requisite specimens.
The culture and sensitivity of any isolated organism should inform the selection of the antibiotic treatment.
• For empirical management of an abscess originating from oral, otogenic, or sinus sources: Administer cefotaxime 2 g intravenously every 4 hours or ceftriaxone 2 g intravenously every 12 hours, alongside metronidazole 7.5 mg/kg intravenously every 8 hours (not to surpass 4 g per day; utilize 15 mg/kg as an initial loading dose).
• As an alternative for an oral source, administer penicillin G at a dosage of 24 million units per day in divided doses every 4 hours, and metronidazole at 7.5 mg/kg intravenously every 6 hours.
For suspected hematogenous dissemination, administer vancomycin (30 mg/kg in two split doses) alongside metronidazole and either cefotaxime or ceftriaxone at the specified dosages.
Postsurgical infections should be empirically managed with vancomycin at a dosage of 30 mg/kg administered in two separate doses, alongside ceftazidime (2 g intravenously every 8 hours) or cefepime (2 g intravenously every 8 hours). In cases where cultures indicate Methicillin-Sensitive Staphylococcus aureus (MSSA), substitute vancomycin with nafcillin or oxacillin (2 g IV every 4 hours) due to superior central nervous system penetration.
• For abscesses resulting from penetrating trauma, administer empirical treatment with vancomycin and either ceftriaxone or cefotaxime at the specified dosages. Substitute vancomycin with nafcillin or oxacillin upon confirmation of MSSA.
• A duration of 6 to 8 weeks, or longer, of intravenous therapy is required, accompanied by further CT scan evaluations.
• Steroids should be administered if mass effect is evident and mental status is impaired.
Surgical intervention serves both diagnostic and therapeutic purposes. Aspiration is a straightforward operation conducted under local anesthetic that facilitates prompt alleviation of elevated intracranial pressure.
New methodologies for the management of brain abscesses encompass ioMRI-guided aspiration and ioMRI-guided resection.
COMPLICATIONS
Cerebral herniation may manifest in 15–20% of patients. High morbidity correlates with persisting neurological impairments in patients with a history of brain abscesses.
Hemiparesis has been documented in 50%. Epilepsy occurs in less than 50%. The primary determinant of death is the neurological condition at the time of presentation.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Patients frequently necessitate consecutive CT or MRI scans for a minimum duration of one year after the conclusion of antibiotic treatment.
BRAIN ABSCESS
FUNDAMENTAL DESCRIPTION
A brain abscess is a localized accumulation of purulent material inside the brain parenchyma resulting from an infectious agent, such as bacteria, fungus, or protozoa. The formation may exhibit a distinct abscess wall or comprise an inflammatory condition (cerebritis).
Epidemiology
Frequency
• Uncommon infection, present in 0.2–1.3% of extensive postmortem studies, and in 1 out of 10,000 hospital admissions. • 25% of brain abscesses occur in pediatric patients. • Median age of infection: 30–45 years.
RISK FACTORS • Sinusitis • Otitis media • Inadequate dental hygiene
• Endocarditis • Bacteremia due to indwelling central lines and intravenous drug usage • Osler–Weber–Rendu syndrome
• Prior brain injury • Immunocompromised state • Cyanotic congenital heart disease
• Intrapulmonary shunting in individuals with arteriovenous malformations
GENERAL PREVENTION • Sinusitis and otitis must be addressed in all patients.
• Proper dental hygiene is essential in the management of apical abscesses, particularly in the upper molars.
PATHOPHYSIOLOGY • Infection may access the brain through the following mechanisms:
- Direct transmission from the sinuses, orbit, dental structures, mastoid, middle ear, and meninges – Post-trauma or neurosurgical intervention – Hematogenous dissemination
ETIOLOGY • The characteristics of the organisms present in the infection frequently
pertains to the method of transmission:
• Middle ear, paranasal sinuses, odontogenic infections - Mixed infections involving anaerobes, microaerophilic streptococci, viridans streptococci, Streptococcus milleri, S. pneumoniae (infrequent), Haemophilus, Fusobacterium, Prevotella melaninogenica, Enterobacteriaceae, Pseudomonas
• Trauma and postoperative considerations: Staphylococcus aureus – Pseudomonas – Additional gram-negative bacteria
– Propionibacterium • Hematogenous:
– Staphylococcus aureus – Salmonella
– Listeria monocytogenes
- Streptococci (notably Streptococcus viridans) Klebsiella pneumoniae
– Escherichia coli, Proteus species – Pseudomonas – Bacteroides species (including Bacteroides fragilis) – Actinomyces – Fungi
• Immunocompromised individuals: – Toxoplasma gondii – Listeria species – Rhodococcus equi
Nocardia asteroides
Aspergillus species, Cryptococcus neoformans, Coccidioides immitis, Candida species, Zygomycetes, Cladosporium trichoides, Curvularia species.
• Immigrants originating from endemic nations: – Taenia solium – Entamoeba histolytica – Schistosoma japonicum – Paragonimus spp.
DIAGNOSIS
The clinical signs are often modest and nonspecific.
• Common symptoms consist of headache lasting less than two weeks (75% of cases), neck stiffness (25%), alterations in mental state, nausea, and vomiting.
• Low-grade fevers may occur in 45–50% of cases.
• Focal neurological abnormalities seen in 50% of cases
• Seizures occur in 25% of cases and may serve as the primary indication for CT screening.
Deficits in the third and sixth cranial nerves, along with papilledema, signify elevated intracranial pressure and cerebral edema. Diagnosis is contingent upon the abscess's location, the causative organism, and any prior conditions that may have contributed to its formation.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• The white blood cell count is high in 60–70% of cases.
• ESR may elevate in 90% of cases.
• Lumbar puncture poses significant risks, particularly in patients exhibiting focal neurological symptoms. If the cerebrospinal fluid mimics that of bacterial meningitis, one may assume a ruptured abscess.
the ventricle
• Microbiological diagnosis • Positive blood cultures • Stereotactic abscess aspiration, cultures, and specific stains • 16S ribosomal sequencing of the aspirate • Serology: Toxoplasmosis, neurocysticercosis
Imaging
CT and MRI are essential diagnostic modalities.
Gadolinium-enhanced MRI provides superior visualization of the brainstem, whereas diffusion-weighted MRI is employed to distinguish between brain abscesses and neoplastic lesions.
• Serial scans must be conducted, particularly when empirical treatment is used.
Ring lesions may endure for a duration of 3 to 4 months, even with appropriate treatment.
Diagnostic Procedures and Additional Methods
• Stereotactic aspiration: The preferred method when the abscess is readily accessible and exceeds 2.5 cm in diameter. • Craniotomy with aspiration: Indicated in regions requiring direct sight of blood vessels when the abscess measures over 2.5 cm in diameter.
DIFFERENTIAL DIAGNOSIS • Epidural and subdural empyema • Septic dural sinus thrombosis • Mycotic aneurysms • Septic cerebral emboli with infarcts • Acute focal necrotizing encephalitis • Metastatic or primary brain tumors • Pyogenic meningitis • Hematoma • Radiation necrosis
ADDITIONAL TREATMENT
Comprehensive Strategies
The antibiotic treatment is contingent upon the probable source of the infection.
• Commence empiric antibiotics promptly following the acquisition of the requisite specimens.
The culture and sensitivity of any isolated organism should inform the selection of the antibiotic treatment.
• For empirical management of an abscess originating from oral, otogenic, or sinus sources: Administer cefotaxime 2 g intravenously every 4 hours or ceftriaxone 2 g intravenously every 12 hours, alongside metronidazole 7.5 mg/kg intravenously every 8 hours (not to surpass 4 g per day; utilize 15 mg/kg as an initial loading dose).
• As an alternative for an oral source, administer penicillin G at a dosage of 24 million units per day in divided doses every 4 hours, and metronidazole at 7.5 mg/kg intravenously every 6 hours.
For suspected hematogenous dissemination, administer vancomycin (30 mg/kg in two split doses) alongside metronidazole and either cefotaxime or ceftriaxone at the specified dosages.
Postsurgical infections should be empirically managed with vancomycin at a dosage of 30 mg/kg administered in two separate doses, alongside ceftazidime (2 g intravenously every 8 hours) or cefepime (2 g intravenously every 8 hours). In cases where cultures indicate Methicillin-Sensitive Staphylococcus aureus (MSSA), substitute vancomycin with nafcillin or oxacillin (2 g IV every 4 hours) due to superior central nervous system penetration.
• For abscesses resulting from penetrating trauma, administer empirical treatment with vancomycin and either ceftriaxone or cefotaxime at the specified dosages. Substitute vancomycin with nafcillin or oxacillin upon confirmation of MSSA.
• A duration of 6 to 8 weeks, or longer, of intravenous therapy is required, accompanied by further CT scan evaluations.
• Steroids should be administered if mass effect is evident and mental status is impaired.
Surgical intervention serves both diagnostic and therapeutic purposes. Aspiration is a straightforward operation conducted under local anesthetic that facilitates prompt alleviation of elevated intracranial pressure.
New methodologies for the management of brain abscesses encompass ioMRI-guided aspiration and ioMRI-guided resection.
COMPLICATIONS
Cerebral herniation may manifest in 15–20% of patients. High morbidity correlates with persisting neurological impairments in patients with a history of brain abscesses.
Hemiparesis has been documented in 50%. Epilepsy occurs in less than 50%. The primary determinant of death is the neurological condition at the time of presentation.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Patients frequently necessitate consecutive CT or MRI scans for a minimum duration of one year after the conclusion of antibiotic treatment.
- Published on
Infectious Disease - Botulism
Fundamental Description: A syndrome caused by neurotoxins released by Clostridium botulinum. Botulinum neurotoxin (BoNT) ranks among the most hazardous chemicals recognized by humanity.
• Botulism manifests in five epidemiological types. – Foodborne botulism – Infant botulism – Wound botulism – Intestinal colonization and adult infectious botulism – Inhalational botulism
Incubation: Symptoms manifest 12–36 hours post-ingestion of the poison.
EPIDEMIOLOGY
Incidence
• Botulism is an uncommon yet potentially fatal condition. • Minor outbreaks may result from either commercially or home-canned foods.
In the United States, the majority of instances arise in babies, with roughly one-fourth attributed to dietary sources and a minor proportion resulting from wounds.
RISK FACTORS
Homemade food fermentation combined with home canning elevates dangers.
The mortality rate is elevated in patients above 60 years of age. The consumption of honey by newborns poses a danger for gastrointestinal colonization and toxin generation.
Iatrogenic botulism has been documented following the administration of unapproved botulinum toxin A.
Physicians must recognize the potential for wound botulism among intravenous drug users.
GENERAL PREVENTION MEASURES
• Exercise caution while canning low-acid foods, including corn, asparagus, beans, and beets.
• If goods have been home-canned, boil them for 10 minutes before consumption.
Avoid administering honey to infants under one year of age.
• Conduct an expedited assessment of prospective cases to prevent possible epidemics.
Avoid consuming food from bulging cans.
ETIOLOGY
• C. botulinum comprises a group of anaerobic, gram-positive bacilli that generate spores and highly potent neurotoxins.
The organism is classified from A to G based on the antibodies generated against the produced neurotoxic.
Human disease is linked to toxin types A, B, E, and F.
Type A is frequently located in the western United States and China.
Type B is located in the eastern United States and Europe.
Type F is prevalent in Alaska, has a global distribution, and is frequently linked to fish items.
• Spores are located in soil and marine sediment.
• Spores withstand boiling but can be eradicated by heating to 120°C.
• Owing to its extreme toxicity, BoNT is regarded as a possible biological warfare agent.
DIAGNOSIS
• Bilateral cranial neuropathies • Bilateral descending weakness • Absence of fever • The patient remains conscious and alert as the syndrome advances • No sensory abnormalities are present. Clinical suspicion is fundamental for diagnosis.
DIAGNOSTIC TESTS AND INTERPRETATION LABORATORY
• Identification of the toxin in serum, feces, or food samples • The sensitivity of the mouse bioassay has recently been established at 68% in patients with wound botulism
DIFFERENTIAL DIAGNOSIS
• Myasthenia gravis • Eaton–Lambert syndrome • Tick paralysis • Miller Fisher form of Guillain–Barré syndrome
• Cerebrovascular accident • Poliomyelitis • Heavy metal poisoning
ADDITIONAL TREATMENT
Comprehensive Strategies
• Supportive care is provided. • Antitoxin is available, targeting toxin types A, B, and E. • Antibiotic therapy is supplied for wound botulism following antitoxin administration. • Intravenous human botulism immunoglobulin (BIG-IV) has been produced and utilized in newborns. It should be administered promptly at the onset of the sickness.
CONTINUING CARE FOLLOW-UP SUGGESTIONS
• Patients frequently require extended rehabilitation. • In comparison to controls, those who recovered from botulism were more prone to experience weariness, weakness, dizziness, and respiratory difficulties.
Fundamental Description: A syndrome caused by neurotoxins released by Clostridium botulinum. Botulinum neurotoxin (BoNT) ranks among the most hazardous chemicals recognized by humanity.
• Botulism manifests in five epidemiological types. – Foodborne botulism – Infant botulism – Wound botulism – Intestinal colonization and adult infectious botulism – Inhalational botulism
Incubation: Symptoms manifest 12–36 hours post-ingestion of the poison.
EPIDEMIOLOGY
Incidence
• Botulism is an uncommon yet potentially fatal condition. • Minor outbreaks may result from either commercially or home-canned foods.
In the United States, the majority of instances arise in babies, with roughly one-fourth attributed to dietary sources and a minor proportion resulting from wounds.
RISK FACTORS
Homemade food fermentation combined with home canning elevates dangers.
The mortality rate is elevated in patients above 60 years of age. The consumption of honey by newborns poses a danger for gastrointestinal colonization and toxin generation.
Iatrogenic botulism has been documented following the administration of unapproved botulinum toxin A.
Physicians must recognize the potential for wound botulism among intravenous drug users.
GENERAL PREVENTION MEASURES
• Exercise caution while canning low-acid foods, including corn, asparagus, beans, and beets.
• If goods have been home-canned, boil them for 10 minutes before consumption.
Avoid administering honey to infants under one year of age.
• Conduct an expedited assessment of prospective cases to prevent possible epidemics.
Avoid consuming food from bulging cans.
ETIOLOGY
• C. botulinum comprises a group of anaerobic, gram-positive bacilli that generate spores and highly potent neurotoxins.
The organism is classified from A to G based on the antibodies generated against the produced neurotoxic.
Human disease is linked to toxin types A, B, E, and F.
Type A is frequently located in the western United States and China.
Type B is located in the eastern United States and Europe.
Type F is prevalent in Alaska, has a global distribution, and is frequently linked to fish items.
• Spores are located in soil and marine sediment.
• Spores withstand boiling but can be eradicated by heating to 120°C.
• Owing to its extreme toxicity, BoNT is regarded as a possible biological warfare agent.
DIAGNOSIS
• Bilateral cranial neuropathies • Bilateral descending weakness • Absence of fever • The patient remains conscious and alert as the syndrome advances • No sensory abnormalities are present. Clinical suspicion is fundamental for diagnosis.
DIAGNOSTIC TESTS AND INTERPRETATION LABORATORY
• Identification of the toxin in serum, feces, or food samples • The sensitivity of the mouse bioassay has recently been established at 68% in patients with wound botulism
DIFFERENTIAL DIAGNOSIS
• Myasthenia gravis • Eaton–Lambert syndrome • Tick paralysis • Miller Fisher form of Guillain–Barré syndrome
• Cerebrovascular accident • Poliomyelitis • Heavy metal poisoning
ADDITIONAL TREATMENT
Comprehensive Strategies
• Supportive care is provided. • Antitoxin is available, targeting toxin types A, B, and E. • Antibiotic therapy is supplied for wound botulism following antitoxin administration. • Intravenous human botulism immunoglobulin (BIG-IV) has been produced and utilized in newborns. It should be administered promptly at the onset of the sickness.
CONTINUING CARE FOLLOW-UP SUGGESTIONS
• Patients frequently require extended rehabilitation. • In comparison to controls, those who recovered from botulism were more prone to experience weariness, weakness, dizziness, and respiratory difficulties.
- Published on
Infectious Disease- Blepharitis and Chalazion
BASICS DESCRIPTION • Blepharitis is an eyelid infection characterized by inflammation of the lid edges. It encompasses the subsequent elements:
- Anterior – inflammation near the follicular root of the eyelashes – Posterior – internal segment of the eyelid – Granulomatous
Chalazion is a painless, granulomatous infection of a meibomian gland resulting in a nodule in the eyelid.
EPIDEMIOLOGY Incidence • Blepharitis is a prevalent ailment encountered by primary care physicians and ophthalmologists.
Posterior blepharitis is typically linked to rosacea and seborrheic dermatitis.
FACTORS OF RISK
Over seventy-five percent of individuals with blepharitis linked to atopic dermatitis exhibit a positive culture for Staphylococcus aureus. A positive culture does not inherently indicate an active infection, making clinical correlation essential.
PATHOPHYSIOLOGY • Bacterial organisms may influence meibomian gland secretion. • Associated alterations in the secretions from meibomian glands may also occur.
ETIOLOGY • Nearly all infections that impact the skin and colonize the eyelids from adjacent regions, such as the scalp and nostrils, can lead to infectious illnesses of the eyelid (1).
The predominant etiological agents are Staphylococcus species, especially Staphylococcus aureus. Additional pathogens encompass the following:
Bacillus anthracis, Bacillus cereus, Blastomyces dermatitidis, Candida species, Clostridium species, Cryptococcus neoformans
– Haemophilus ducreyi – Herpes simplex virus – Herpes zoster virus – Moraxella spp – Mycobacterium TB – Mycobacterium leprae – Phthirus pubis – Poxvirus spp – Proteus mirabilis – Pseudomonas spp – Streptococcus spp – Vaccinia virus
FREQUENTLY CO-OCCURRING CONDITIONS
• Rosacea • Seborrheic dermatitis
DIAGNOSTIC HISTORY
• Common symptoms encompass persistent irritation, a burning sensation, slight erythema, and intermittent pruritus of the eyelids.
• Certain patients report experiencing clouded eyesight
PHYSICAL EXAMINATION
• Acute blepharitis is characterized by the presence of pus collections and an ulcerative margin. • • Chronic blepharitis typically presents with loss or misdirection of eyelashes, telangiectasia, and a swollen lid margin.
Superficial eyelid involvement is the predominant manifestation of staphylococcal eyelid illness, typically characterized by hyperemia and telangiectasia at the eyelid edge.
DIAGNOSTIC TESTS AND INTERPRETATION
Imaging
Ophthalmologists may perform slit lamp examinations.
TREATMENT MEDICATION
• Typically, the management of blepharitis involves warm compresses, rigorous eyelid cleanliness, and topical antibiotics (2).
A firm massage utilizing a 50:50 blend of baby shampoo and water with a cotton-tipped applicator promotes the release of oils from the meibomian glands.
Topical ocular treatments for staphylococcal blepharitis comprise bacitracin or erythromycin (either b.i.d. or q.i.d. for 2 weeks), gentamicin, and 1% mercuric oxide.
In chronic instances of blepharitis, cultures should be collected when patients exhibit persistent blepharitis unresponsive to topical medicines. Systemic antibiotics applicable in these instances include dicloxacillin (500 mg q.i.d.), quinolones, or azithromycin.
• In cases of persistent, nontender chalazion, incision and curettage may be performed. The inflammatory material can be excised through a vertical or, if required, a horizontal conjunctival incision. In the absence of infection, corticosteroids may be administered via intralesional injection.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
In rare instances of necrotizing fasciitis affecting the eyelids, immediate surgical debridement is required.
CONTINUED MANAGEMENT POST-TREATMENT GUIDELINES
Basal cell carcinoma, squamous cell carcinoma, or meibomian gland carcinoma should be considered for any nonhealing, ulcerative eyelid lesion.
COMPLICATIONS
An external hordeolum (stye) results from a staphylococcal infection of the superficial accessory glands of Zeis or Moll, situated near the eyelid borders. An internal hordeolum arises from a suppurative infection of the oil-secreting meibomian glands located within the tarsal plate of the eyelid
BASICS DESCRIPTION • Blepharitis is an eyelid infection characterized by inflammation of the lid edges. It encompasses the subsequent elements:
- Anterior – inflammation near the follicular root of the eyelashes – Posterior – internal segment of the eyelid – Granulomatous
Chalazion is a painless, granulomatous infection of a meibomian gland resulting in a nodule in the eyelid.
EPIDEMIOLOGY Incidence • Blepharitis is a prevalent ailment encountered by primary care physicians and ophthalmologists.
Posterior blepharitis is typically linked to rosacea and seborrheic dermatitis.
FACTORS OF RISK
Over seventy-five percent of individuals with blepharitis linked to atopic dermatitis exhibit a positive culture for Staphylococcus aureus. A positive culture does not inherently indicate an active infection, making clinical correlation essential.
PATHOPHYSIOLOGY • Bacterial organisms may influence meibomian gland secretion. • Associated alterations in the secretions from meibomian glands may also occur.
ETIOLOGY • Nearly all infections that impact the skin and colonize the eyelids from adjacent regions, such as the scalp and nostrils, can lead to infectious illnesses of the eyelid (1).
The predominant etiological agents are Staphylococcus species, especially Staphylococcus aureus. Additional pathogens encompass the following:
Bacillus anthracis, Bacillus cereus, Blastomyces dermatitidis, Candida species, Clostridium species, Cryptococcus neoformans
– Haemophilus ducreyi – Herpes simplex virus – Herpes zoster virus – Moraxella spp – Mycobacterium TB – Mycobacterium leprae – Phthirus pubis – Poxvirus spp – Proteus mirabilis – Pseudomonas spp – Streptococcus spp – Vaccinia virus
FREQUENTLY CO-OCCURRING CONDITIONS
• Rosacea • Seborrheic dermatitis
DIAGNOSTIC HISTORY
• Common symptoms encompass persistent irritation, a burning sensation, slight erythema, and intermittent pruritus of the eyelids.
• Certain patients report experiencing clouded eyesight
PHYSICAL EXAMINATION
• Acute blepharitis is characterized by the presence of pus collections and an ulcerative margin. • • Chronic blepharitis typically presents with loss or misdirection of eyelashes, telangiectasia, and a swollen lid margin.
Superficial eyelid involvement is the predominant manifestation of staphylococcal eyelid illness, typically characterized by hyperemia and telangiectasia at the eyelid edge.
DIAGNOSTIC TESTS AND INTERPRETATION
Imaging
Ophthalmologists may perform slit lamp examinations.
TREATMENT MEDICATION
• Typically, the management of blepharitis involves warm compresses, rigorous eyelid cleanliness, and topical antibiotics (2).
A firm massage utilizing a 50:50 blend of baby shampoo and water with a cotton-tipped applicator promotes the release of oils from the meibomian glands.
Topical ocular treatments for staphylococcal blepharitis comprise bacitracin or erythromycin (either b.i.d. or q.i.d. for 2 weeks), gentamicin, and 1% mercuric oxide.
In chronic instances of blepharitis, cultures should be collected when patients exhibit persistent blepharitis unresponsive to topical medicines. Systemic antibiotics applicable in these instances include dicloxacillin (500 mg q.i.d.), quinolones, or azithromycin.
• In cases of persistent, nontender chalazion, incision and curettage may be performed. The inflammatory material can be excised through a vertical or, if required, a horizontal conjunctival incision. In the absence of infection, corticosteroids may be administered via intralesional injection.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
In rare instances of necrotizing fasciitis affecting the eyelids, immediate surgical debridement is required.
CONTINUED MANAGEMENT POST-TREATMENT GUIDELINES
Basal cell carcinoma, squamous cell carcinoma, or meibomian gland carcinoma should be considered for any nonhealing, ulcerative eyelid lesion.
COMPLICATIONS
An external hordeolum (stye) results from a staphylococcal infection of the superficial accessory glands of Zeis or Moll, situated near the eyelid borders. An internal hordeolum arises from a suppurative infection of the oil-secreting meibomian glands located within the tarsal plate of the eyelid
- Published on
Infectious Disease – Blastomycosis
FUNDAMENTAL DESCRIPTION
Acute or chronic infection resulting from Blastomyces dermatitidis, a dimorphic fungus present in soil.
EPIDEMIOLOGY
Occurrence
• Annual incidence ranges from 0.3 to 1.8 incidents per 100,000 (1).
• Up to 7.4 hospital admissions per 1 million individuals in endemic areas (1).
RISK FACTOR
• Location: Endemic in soil adjacent to aquatic environments in the Southeastern United States and the valleys of the Mississippi, Ohio, and St. Lawrence Rivers. Additionally, the Mediterranean coast, South America, Mexico, and Africa. Previously regarded as more common in middle-aged men, but more likely attributed to environmental exposures.
• Immunocompromised individuals are at heightened risk for more severe disease and adverse outcomes.
GENERAL PREVENTION MEASURES
Mitigation of exposure; utilization of breathing masks for individuals at occupational risk
Pathophysiology
• Inhalation of conidia from B. dermatitidis may lead to secondary hematogenous dissemination.
The immune system is more efficient against conidia than against the yeast form. Blastomyces transform into budding yeast within tissue, thereby exhibiting reduced vulnerability to immune system eradication.
• Reactivation in immunocompromised individuals.
ETIOLOGY
Dimorphic fungus, Blastomyces dermatitidis
HISTORY OF DIAGNOSIS
• Acute pneumonia: Abrupt manifestation of symptoms akin to bacterial pneumonia, encompassing:
- Pyrexia, nocturnal diaphoresis
- Productive cough, dyspnea, and pleuritic chest discomfort (60–90%)
– Rash (60 percent)
• Chronic pneumonia: Gradual emergence of symptoms akin to pulmonary tuberculosis
- Pyrexia, nocturnal diaphoresis, weight reduction
Mild productive cough, occasionally accompanied by chest discomfort and hemoptysis.
• Additional factors (contingent upon the infection site):
– Eruption – Asymptomatic soft-tissue edema
Meningitis or localized neurological impairment
PHYSICAL EXAMINATION
• Pulmonary: Auscultatory findings include crackles and rhonchi.
• Dermatological lesions: Generally non-painful papules or nodules.
. May present as either verrucous or ulcerated and cause discomfort.
• Non-tender soft tissue edema, occasionally accompanied by a draining tract.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory
• There is no commercially available serological test due to cross-reactivity with other endemic mycoses.
• Urine antigen testing is accessible but not extensively utilized due to cross-reactivity.
Imaging
Preliminary strategy
Chest radiograph (CXR): Mass, many nodules, lobar infiltration, cavitation. Lymphadenopathy is infrequent.
Subsequent Actions & Unique Considerations
Additional clinical manifestations include genitourinary tract infections, septic arthritis, osteomyelitis, ocular infections, central nervous system infections (meningitis, cerebral abscess), and oropharyngeal abscess (1).
Diagnostic Procedures and Additional Methods
• Culture: 86% positive for sputum; 92% positive for bronchoalveolar lavage (BAL)
• Wet preparation: 46% sensitivity (multiple specimens utilizing KOH or calcofluor white)
• Attributes: Substantial yeast structures (8–15 mm in diameter) exhibiting a solitary broad-based bud
Pathological Observations
• Pyogranulomas
• Fungal elements are more readily observed with methenamine silver stain or Periodic acid-Schiff stain (PAS).
DIFFERENTIAL DIAGNOSIS
• Atypical pneumonia (acute pneumonia)
Lung carcinoma or mycobacterial infection (chronic pneumonia)
• Squamous cell carcinoma (cutaneous lesions)
MEDICATION FOR TREATMENT
• Pulmonary or disseminated non-central nervous system illness (2):
- Administer Amphotericin B (or lipid/liposomal formulation) for 2 weeks, followed by itraconazole 200 mg orally three times daily for 3 days, then 200 mg orally twice daily for 6–12 months.
For mild to moderate disease, administer itraconazole 200 mg orally three times daily for 3 days, followed by 200 mg orally twice daily for 6 to 12 months. • CNS disease: - Administer Amphotericin B (lipid/liposomal formulation) at a dosage of 3–5 mg/kg intravenously for a duration of 4–6 weeks, followed by oral azole therapy for a minimum of 12 months.
Itraconazole 200 mg orally three times daily or twice daily. Alternatively, provide Fluconazole 800 mg orally each day. Voriconazole 200–400 mg orally, twice daily. • In immunocompromised individuals: Administer Amphotericin B for 2 weeks, followed by itraconazole 200 mg orally three times daily for 3 days, then 200 mg orally twice daily for 12 months.
– Contemplate lifelong administration of itraconazole 200 milligrams orally daily.
Pediatric Considerations
• Treatment for mild disease: Itraconazole, 10 mg/kg daily for 6–12 months. • Treatment for severe disease: Amphotericin (or liposomal) followed by itraconazole.
Considerations During Pregnancy
• Prescription: Amphotericin B only, due to the contraindication of azoles during pregnancy.
SUPPLEMENTARY THERAPY
Comprehensive Measures
Continuous surveillance for the toxicity of antifungal medicines.
SURGERY/OTHER PROCEDURES
Uncommon, in instances of central nervous system mass or abscess.
INPATIENT CONSIDERATIONS
Preliminary Stabilization
• The death rate for ARDS, even with proper treatment, ranges from 50% to 89%.
• Diligent monitoring of neurological assessments in central nervous system disorders.
Admission Criteria: • Immunosuppression • Respiratory distress • Requirement for intravenous therapy
CONTINUED MANAGEMENT POST-TREATMENT GUIDELINES
Surveillance of the patient following treatment for approximately six months, due to the potential for relapse.
Patient Surveillance
• Therapeutic drug monitoring for itraconazole is advised after two weeks of treatment: Does not require to be accurate through or peak. The objective is to exceed 1.0 μg/mL and remain below 10 μg/mL (2).
• Conduct liver function tests (LFTs) every three months at a minimum during azole therapy.
NUTRITION
Itraconazole must be administered with food.
PATIENT EDUCATION
• Address the possibility of drug–drug interactions associated with itraconazole administration.
• Anxiety of recurrence despite the availability of suitable treatment (2).
PROGNOSIS
• A cure without relapse occurs in 90–97% of immunocompetent individuals treated with amphotericin.
• 40% mortality rate in immunocompromised individuals (bone marrow transplant [BMT], AIDS); marginally improved outcomes in solid-organ transplant recipients.
Considerations During Pregnancy
Results: Early diagnosis can lead to favorable outcomes; however, pregnant women are at increased risk for more severe disease due to their mild immunosuppression.
FUNDAMENTAL DESCRIPTION
Acute or chronic infection resulting from Blastomyces dermatitidis, a dimorphic fungus present in soil.
EPIDEMIOLOGY
Occurrence
• Annual incidence ranges from 0.3 to 1.8 incidents per 100,000 (1).
• Up to 7.4 hospital admissions per 1 million individuals in endemic areas (1).
RISK FACTOR
• Location: Endemic in soil adjacent to aquatic environments in the Southeastern United States and the valleys of the Mississippi, Ohio, and St. Lawrence Rivers. Additionally, the Mediterranean coast, South America, Mexico, and Africa. Previously regarded as more common in middle-aged men, but more likely attributed to environmental exposures.
• Immunocompromised individuals are at heightened risk for more severe disease and adverse outcomes.
GENERAL PREVENTION MEASURES
Mitigation of exposure; utilization of breathing masks for individuals at occupational risk
Pathophysiology
• Inhalation of conidia from B. dermatitidis may lead to secondary hematogenous dissemination.
The immune system is more efficient against conidia than against the yeast form. Blastomyces transform into budding yeast within tissue, thereby exhibiting reduced vulnerability to immune system eradication.
• Reactivation in immunocompromised individuals.
ETIOLOGY
Dimorphic fungus, Blastomyces dermatitidis
HISTORY OF DIAGNOSIS
• Acute pneumonia: Abrupt manifestation of symptoms akin to bacterial pneumonia, encompassing:
- Pyrexia, nocturnal diaphoresis
- Productive cough, dyspnea, and pleuritic chest discomfort (60–90%)
– Rash (60 percent)
• Chronic pneumonia: Gradual emergence of symptoms akin to pulmonary tuberculosis
- Pyrexia, nocturnal diaphoresis, weight reduction
Mild productive cough, occasionally accompanied by chest discomfort and hemoptysis.
• Additional factors (contingent upon the infection site):
– Eruption – Asymptomatic soft-tissue edema
Meningitis or localized neurological impairment
PHYSICAL EXAMINATION
• Pulmonary: Auscultatory findings include crackles and rhonchi.
• Dermatological lesions: Generally non-painful papules or nodules.
. May present as either verrucous or ulcerated and cause discomfort.
• Non-tender soft tissue edema, occasionally accompanied by a draining tract.
DIAGNOSTIC EXAMINATIONS AND ANALYSIS
Laboratory
• There is no commercially available serological test due to cross-reactivity with other endemic mycoses.
• Urine antigen testing is accessible but not extensively utilized due to cross-reactivity.
Imaging
Preliminary strategy
Chest radiograph (CXR): Mass, many nodules, lobar infiltration, cavitation. Lymphadenopathy is infrequent.
Subsequent Actions & Unique Considerations
Additional clinical manifestations include genitourinary tract infections, septic arthritis, osteomyelitis, ocular infections, central nervous system infections (meningitis, cerebral abscess), and oropharyngeal abscess (1).
Diagnostic Procedures and Additional Methods
• Culture: 86% positive for sputum; 92% positive for bronchoalveolar lavage (BAL)
• Wet preparation: 46% sensitivity (multiple specimens utilizing KOH or calcofluor white)
• Attributes: Substantial yeast structures (8–15 mm in diameter) exhibiting a solitary broad-based bud
Pathological Observations
• Pyogranulomas
• Fungal elements are more readily observed with methenamine silver stain or Periodic acid-Schiff stain (PAS).
DIFFERENTIAL DIAGNOSIS
• Atypical pneumonia (acute pneumonia)
Lung carcinoma or mycobacterial infection (chronic pneumonia)
• Squamous cell carcinoma (cutaneous lesions)
MEDICATION FOR TREATMENT
• Pulmonary or disseminated non-central nervous system illness (2):
- Administer Amphotericin B (or lipid/liposomal formulation) for 2 weeks, followed by itraconazole 200 mg orally three times daily for 3 days, then 200 mg orally twice daily for 6–12 months.
For mild to moderate disease, administer itraconazole 200 mg orally three times daily for 3 days, followed by 200 mg orally twice daily for 6 to 12 months. • CNS disease: - Administer Amphotericin B (lipid/liposomal formulation) at a dosage of 3–5 mg/kg intravenously for a duration of 4–6 weeks, followed by oral azole therapy for a minimum of 12 months.
Itraconazole 200 mg orally three times daily or twice daily. Alternatively, provide Fluconazole 800 mg orally each day. Voriconazole 200–400 mg orally, twice daily. • In immunocompromised individuals: Administer Amphotericin B for 2 weeks, followed by itraconazole 200 mg orally three times daily for 3 days, then 200 mg orally twice daily for 12 months.
– Contemplate lifelong administration of itraconazole 200 milligrams orally daily.
Pediatric Considerations
• Treatment for mild disease: Itraconazole, 10 mg/kg daily for 6–12 months. • Treatment for severe disease: Amphotericin (or liposomal) followed by itraconazole.
Considerations During Pregnancy
• Prescription: Amphotericin B only, due to the contraindication of azoles during pregnancy.
SUPPLEMENTARY THERAPY
Comprehensive Measures
Continuous surveillance for the toxicity of antifungal medicines.
SURGERY/OTHER PROCEDURES
Uncommon, in instances of central nervous system mass or abscess.
INPATIENT CONSIDERATIONS
Preliminary Stabilization
• The death rate for ARDS, even with proper treatment, ranges from 50% to 89%.
• Diligent monitoring of neurological assessments in central nervous system disorders.
Admission Criteria: • Immunosuppression • Respiratory distress • Requirement for intravenous therapy
CONTINUED MANAGEMENT POST-TREATMENT GUIDELINES
Surveillance of the patient following treatment for approximately six months, due to the potential for relapse.
Patient Surveillance
• Therapeutic drug monitoring for itraconazole is advised after two weeks of treatment: Does not require to be accurate through or peak. The objective is to exceed 1.0 μg/mL and remain below 10 μg/mL (2).
• Conduct liver function tests (LFTs) every three months at a minimum during azole therapy.
NUTRITION
Itraconazole must be administered with food.
PATIENT EDUCATION
• Address the possibility of drug–drug interactions associated with itraconazole administration.
• Anxiety of recurrence despite the availability of suitable treatment (2).
PROGNOSIS
• A cure without relapse occurs in 90–97% of immunocompetent individuals treated with amphotericin.
• 40% mortality rate in immunocompromised individuals (bone marrow transplant [BMT], AIDS); marginally improved outcomes in solid-organ transplant recipients.
Considerations During Pregnancy
Results: Early diagnosis can lead to favorable outcomes; however, pregnant women are at increased risk for more severe disease due to their mild immunosuppression.
- Published on
Infectious Disease - Bacillary Angiomatosis/Peliosis Hepatis
DESCRIPTION
• A rare, vascular proliferative infectious disease affecting the skin and internal organs, predominantly observed in immunosuppressed persons, particularly those with T-cell deficits, such as HIV-positive patients. The name bacillary angiomatosis (BA) mostly refers to the cutaneous or disseminated form, whereas peliosis hepatica (PH) denotes the visceral form of this feverish sickness associated with Bartonella species.
EPIDEMIOLOGY
Prevalence This disease, encountered globally, is rare; isolated cases have been reported from various regions worldwide.
RISK FACTORS • HIV infection (CD4 <100) (1) • Other types of immunosuppression • Unsanitary settings, exposure to felines
COMPREHENSIVE PREVENTION
• Concerning cats for people who are HIV-positive or otherwise immunocompromised: It is advisable to acquire a cat that is over one year old and in good health. The patient must practice meticulous hand hygiene following the cleaning of the litter box. Prevent bites and scratches; wash hands immediately if they occur. Declawing or subjecting a cat to testing is not recommended. • Primary prophylaxis is not advised. Prophylactic administration of a macrolide provides protection against Bartonella infection. The potential requirement for secondary prophylaxis or the indefinite duration of treatment in HIV-positive patients remains undefined.
ETIOLOGY • Bartonella henselae (predominantly BA) and Bartonella quintana (mostly bacteremia). Bartonella species are gram-negative bacteria belonging to the alpha Proteobacteria family. • Infection with B. henselae is associated with cat exposure in individuals with HIV infection. Conversely, BA attributed to B. quintana is linked to body louse infection and homelessness.
DIAGNOSIS HISTORY
• The incubation period lasts a minimum of one week. • Clinical manifestations vary from isolated bacteremia to cutaneous and visceral (PH) disease, together with involvement of several organs (skin, bones, central nervous system). • If left untreated, it may be lethal. • BA: – Constitutional: Pyrexia, malaise, cachexia, anemia • PH: – Constitutional: Chronic fever, fatigue, weight reduction, stomach discomfort - Gastrointestinal manifestations: Nausea, emesis • Symptoms related to other organs or systems are contingent upon the individual body component involved (e.g., ostealgia, neurological impairments, etc.).
PHYSICAL EXAMINATION
• BA: – Dermatological symptoms (93% of patients): — Elevated, vivid red papules, ranging from one to hundreds in quantity and measuring from 1 mm to several centimeters in size, observed in two-thirds of patients. – Minor lesions may be obscured by a thinned epidermis, whereas bigger lesions are prone to erosion and hemorrhage. A peripheral collarette is prevalent. Subcutaneous nodular lesions, observed in one-fourth of patients, are typically big and may not exhibit any changes in the overlying skin. Cellulitic plaque-like lesions occur in 5–10% of patients and frequently overlay deeper osseous lesions. Ulcerations and folliculitis lesions are infrequent. Lesions can manifest in any region of the body; many types may develop simultaneously or in succession. - Extracutaneous signs primarily include bone and visceral lesions (liver, spleen), however several other organ/system involvements have been documented, with or without vascular proliferative alterations, painful or painless lymphadenopathy, and cerebral abscesses. Bone disease may initially present solely with pain and may or may not be accompanied by superficial skin sores. • PH: – Significant hepatomegaly, progressing over weeks or months – Splenomegaly – Potential involvement of the skin or other organs
DIAGNOSTIC TESTS AND INTERPRETATION
LAB
Diagnosis is established through the identification of causative organisms in hematoxylin and eosin-stained tissue sections (granular purple material); it may also be confirmed using Warthin-Starry or Brown–Hopps tissue stains. • Organisms manifest either solitarily or in clusters and entanglements. • Acquiring culture is challenging and labor-intensive. The organism can be extracted from the blood using lysis centrifugation cultures. Incubate for a minimum of 21 days. Polymerase chain reaction (PCR) is used for detection and species identification. • The sensitivity of serological tests is diminished in immunocompromised individuals. • Mildly raised transaminases (average ×2 of normal), moderate to severe elevation of alkaline phosphatase (average ×5 of normal), and normal or slightly higher bilirubin levels. Mild to moderate pancytopenia may manifest in the visceral form of the disease. Imaging • Bone disease: Standard bone radiographs reveal well-defined lytic lesions or indistinct areas of significant cortical destruction accompanied by pronounced periosteal response. • CT imaging may demonstrate hepatosplenomegaly and enlargement of intra-abdominal and/or retroperitoneal lymph nodes. Visceral parenchyma may exhibit a diverse consistency. Histopathological Observations • Biopsy or fine-needle aspiration specimens from the skin, liver, and lymph nodes are typically utilized. The pathological pattern is contingent upon the organ affected. • Skin: Lesions exhibit a "epithelioid hemangioma" look, with the presence of organisms demonstrated. • PH: Liver biopsy specimens exhibit significantly dilated, blood-filled cystic areas within the parenchyma. They are frequently linked to a myxoid stroma. Foci of necrosis are observable in advanced instances.
DIFFERENTIAL DIAGNOSIS • BA: – Kaposi’s sarcoma – Pyogenic granulomas – Angiomas – Verruga peruana (bartonellosis, prevalent in South America) • PH: – Kaposi’s sarcoma • Extracutaneous manifestations: – Additional lesions occurring in space – The potential coexistence with Kaposi’s sarcoma must constantly be contemplated.
THERAPY PHARMACEUTICALS
Initial Statement An initial assessment is required to ascertain the degree of organ involvement. Erythromycin 500 mg orally every 6 hours or doxycycline 100 mg every 12 hours (AII) • Treatment duration: BA 3 months; PH 4 months. Extended therapy for immunocompromised individuals. Patients may encounter a Jarisch–Herxheimer reaction and should get prophylactic antipyretic medications within the initial 72 hours of treatment. Second Line • In cases of intolerance to erythromycin or doxycycline, azithromycin or clarithromycin have demonstrated a clinical response (BIII). Combination therapy, incorporating rifampin (300 mg orally twice day) alongside either erythromycin or doxycycline, is advised for immunocompromised patients experiencing acute, life-threatening infections or central nervous system disorders. • TMP-SMX and ciprofloxacin have demonstrated variable clinical efficacy.
INPATIENT CONSIDERATIONS
Criteria for Admission Patients are often managed on an outpatient basis; however, inpatient care and intravenous antibiotics are required for those with significant skin disease, lytic bone lesions, visceral lesions, or fulminant disease.
CONTINUING CARE FOLLOW-UP SUGGESTIONS
• Following the commencement of treatment (about 4–7 days into therapy), substantial enhancement of cutaneous and visceral/other organ lesions is often observed. • Complete resolution typically occurs within 3 to 4 weeks. • Relapses manifest in around 15% of instances. • Treatment failure: Upon relapse, four months of uninterrupted suppressive therapy. Patient Surveillance Clinical monitoring is necessary. • Serial biochemical assays (e.g., liver function tests) may assist in evaluating the therapeutic response in visceral disease. Utilize x-rays or bone scans to assess bone pathology. • The potential for coexistence with Kaposi’s sarcoma should be explored if imaging results do not improve following adequate antibiotic therapy.
COMPLICATIONS
The visceral manifestation of the disease may be exacerbated by anemia, pancytopenia resulting from hypersplenism, and splenic rupture accompanied by hemoperitoneum.
DESCRIPTION
• A rare, vascular proliferative infectious disease affecting the skin and internal organs, predominantly observed in immunosuppressed persons, particularly those with T-cell deficits, such as HIV-positive patients. The name bacillary angiomatosis (BA) mostly refers to the cutaneous or disseminated form, whereas peliosis hepatica (PH) denotes the visceral form of this feverish sickness associated with Bartonella species.
EPIDEMIOLOGY
Prevalence This disease, encountered globally, is rare; isolated cases have been reported from various regions worldwide.
RISK FACTORS • HIV infection (CD4 <100) (1) • Other types of immunosuppression • Unsanitary settings, exposure to felines
COMPREHENSIVE PREVENTION
• Concerning cats for people who are HIV-positive or otherwise immunocompromised: It is advisable to acquire a cat that is over one year old and in good health. The patient must practice meticulous hand hygiene following the cleaning of the litter box. Prevent bites and scratches; wash hands immediately if they occur. Declawing or subjecting a cat to testing is not recommended. • Primary prophylaxis is not advised. Prophylactic administration of a macrolide provides protection against Bartonella infection. The potential requirement for secondary prophylaxis or the indefinite duration of treatment in HIV-positive patients remains undefined.
ETIOLOGY • Bartonella henselae (predominantly BA) and Bartonella quintana (mostly bacteremia). Bartonella species are gram-negative bacteria belonging to the alpha Proteobacteria family. • Infection with B. henselae is associated with cat exposure in individuals with HIV infection. Conversely, BA attributed to B. quintana is linked to body louse infection and homelessness.
DIAGNOSIS HISTORY
• The incubation period lasts a minimum of one week. • Clinical manifestations vary from isolated bacteremia to cutaneous and visceral (PH) disease, together with involvement of several organs (skin, bones, central nervous system). • If left untreated, it may be lethal. • BA: – Constitutional: Pyrexia, malaise, cachexia, anemia • PH: – Constitutional: Chronic fever, fatigue, weight reduction, stomach discomfort - Gastrointestinal manifestations: Nausea, emesis • Symptoms related to other organs or systems are contingent upon the individual body component involved (e.g., ostealgia, neurological impairments, etc.).
PHYSICAL EXAMINATION
• BA: – Dermatological symptoms (93% of patients): — Elevated, vivid red papules, ranging from one to hundreds in quantity and measuring from 1 mm to several centimeters in size, observed in two-thirds of patients. – Minor lesions may be obscured by a thinned epidermis, whereas bigger lesions are prone to erosion and hemorrhage. A peripheral collarette is prevalent. Subcutaneous nodular lesions, observed in one-fourth of patients, are typically big and may not exhibit any changes in the overlying skin. Cellulitic plaque-like lesions occur in 5–10% of patients and frequently overlay deeper osseous lesions. Ulcerations and folliculitis lesions are infrequent. Lesions can manifest in any region of the body; many types may develop simultaneously or in succession. - Extracutaneous signs primarily include bone and visceral lesions (liver, spleen), however several other organ/system involvements have been documented, with or without vascular proliferative alterations, painful or painless lymphadenopathy, and cerebral abscesses. Bone disease may initially present solely with pain and may or may not be accompanied by superficial skin sores. • PH: – Significant hepatomegaly, progressing over weeks or months – Splenomegaly – Potential involvement of the skin or other organs
DIAGNOSTIC TESTS AND INTERPRETATION
LAB
Diagnosis is established through the identification of causative organisms in hematoxylin and eosin-stained tissue sections (granular purple material); it may also be confirmed using Warthin-Starry or Brown–Hopps tissue stains. • Organisms manifest either solitarily or in clusters and entanglements. • Acquiring culture is challenging and labor-intensive. The organism can be extracted from the blood using lysis centrifugation cultures. Incubate for a minimum of 21 days. Polymerase chain reaction (PCR) is used for detection and species identification. • The sensitivity of serological tests is diminished in immunocompromised individuals. • Mildly raised transaminases (average ×2 of normal), moderate to severe elevation of alkaline phosphatase (average ×5 of normal), and normal or slightly higher bilirubin levels. Mild to moderate pancytopenia may manifest in the visceral form of the disease. Imaging • Bone disease: Standard bone radiographs reveal well-defined lytic lesions or indistinct areas of significant cortical destruction accompanied by pronounced periosteal response. • CT imaging may demonstrate hepatosplenomegaly and enlargement of intra-abdominal and/or retroperitoneal lymph nodes. Visceral parenchyma may exhibit a diverse consistency. Histopathological Observations • Biopsy or fine-needle aspiration specimens from the skin, liver, and lymph nodes are typically utilized. The pathological pattern is contingent upon the organ affected. • Skin: Lesions exhibit a "epithelioid hemangioma" look, with the presence of organisms demonstrated. • PH: Liver biopsy specimens exhibit significantly dilated, blood-filled cystic areas within the parenchyma. They are frequently linked to a myxoid stroma. Foci of necrosis are observable in advanced instances.
DIFFERENTIAL DIAGNOSIS • BA: – Kaposi’s sarcoma – Pyogenic granulomas – Angiomas – Verruga peruana (bartonellosis, prevalent in South America) • PH: – Kaposi’s sarcoma • Extracutaneous manifestations: – Additional lesions occurring in space – The potential coexistence with Kaposi’s sarcoma must constantly be contemplated.
THERAPY PHARMACEUTICALS
Initial Statement An initial assessment is required to ascertain the degree of organ involvement. Erythromycin 500 mg orally every 6 hours or doxycycline 100 mg every 12 hours (AII) • Treatment duration: BA 3 months; PH 4 months. Extended therapy for immunocompromised individuals. Patients may encounter a Jarisch–Herxheimer reaction and should get prophylactic antipyretic medications within the initial 72 hours of treatment. Second Line • In cases of intolerance to erythromycin or doxycycline, azithromycin or clarithromycin have demonstrated a clinical response (BIII). Combination therapy, incorporating rifampin (300 mg orally twice day) alongside either erythromycin or doxycycline, is advised for immunocompromised patients experiencing acute, life-threatening infections or central nervous system disorders. • TMP-SMX and ciprofloxacin have demonstrated variable clinical efficacy.
INPATIENT CONSIDERATIONS
Criteria for Admission Patients are often managed on an outpatient basis; however, inpatient care and intravenous antibiotics are required for those with significant skin disease, lytic bone lesions, visceral lesions, or fulminant disease.
CONTINUING CARE FOLLOW-UP SUGGESTIONS
• Following the commencement of treatment (about 4–7 days into therapy), substantial enhancement of cutaneous and visceral/other organ lesions is often observed. • Complete resolution typically occurs within 3 to 4 weeks. • Relapses manifest in around 15% of instances. • Treatment failure: Upon relapse, four months of uninterrupted suppressive therapy. Patient Surveillance Clinical monitoring is necessary. • Serial biochemical assays (e.g., liver function tests) may assist in evaluating the therapeutic response in visceral disease. Utilize x-rays or bone scans to assess bone pathology. • The potential for coexistence with Kaposi’s sarcoma should be explored if imaging results do not improve following adequate antibiotic therapy.
COMPLICATIONS
The visceral manifestation of the disease may be exacerbated by anemia, pancytopenia resulting from hypersplenism, and splenic rupture accompanied by hemoperitoneum.
- Published on
Infectious Disease – Bell’s Palsy
BASICS DESCRIPTION
• Bell’s palsy is characterized by acute, idiopathic, unilateral paralysis of the facial nerve. • Approximately fifty percent of facial nerve palsy cases are classified as “Bell’s palsy.”
Bilateral illness constitutes a rare subtype, accounting for 0.3%.
ETIOLOGY
• Herpes simplex virus • Herpes zoster virus, including herpes zoster oticus • Negative occurrence after to vaccination
Epidemiology
Incidence • Rates range from 13 to 34 instances per 100,000 in the United States. • Incidence peaks among individuals aged 20–35 years and those over 70 years.
• The distribution of boys and females is equal. • Bell's palsy is the predominant etiology of VII nerve palsy in pediatric patients.
RISK FACTORS
• Gestation • Diabetes mellitus • Hypertension in individuals over 40 years
GENERAL PREVENTION
Currently, there is no method to avert Bell's palsy.
DIAGNOSIS
• Sudden onset within one to two days, fast advancement of partial or complete unilateral facial nerve paralysis • Reduced tear and saliva secretion on the affected side • Hyperacusis • Dysgeusia • Retroauricular pain
DIFFERENTIAL DIAGNOSIS
The differential diagnoses list is extensive and includes, among others:
• Echovirus and enterovirus infections • Lyme disease • HIV infection, onset during seroconversion • Otitis media and mastoiditis • Mycobacterium tuberculosis • Syphilis • Infectious meningitis • Rubella • Tetanus • Mycoplasma • Cholesteatoma • Sarcoidosis
• Sjögren’s syndrome • Systemic lupus erythematosus • Melkersson–Rosenthal syndrome • Cerebral aneurysm • Tumor of the parotid gland • Melanoma of the head and neck • Meningioma • Carcinomatous meningitis • Granulomatous meningitis of unknown cause • Guillain-Barré syndrome • Pseudobulbar palsy • Birth trauma • Petrous bone fractures • Iatrogenic/surgical complications
• Paget's disease
• Consider bilateral facial nerve paralysis in the context of:
– Lyme disease – Sarcoidosis
DIAGNOSTIC TESTS & INTERPRETATION
Laboratory
• Electrodiagnostic examinations:
Patients with an incomplete, typical lesion who recover do not require additional investigation. - Electromyography (EMG)
Electroneurography (also known as evoked electromyography)
Imaging
Imaging is required if the clinical presentation is abnormal, development is gradual, or there is no improvement after six months. A CT or MRI scan may be necessary to exclude intracerebral pathology or middle ear disease in complex cases. Recent studies indicate that the ultrasonography diameter of the distal VII nerve is a reliable prognostic indicator for Bell's palsy at three months post-onset.
THERAPY
Early administration of prednisolone markedly enhances the likelihood of full recovery at 3 and 9 months (Recommendation Grade 1A).
Treatment must commence within three days.
The advised dosage is 60–80 mg each day for one week.
• Antivirals are designated for severe facial palsy (Recommendation Grade 2C).
• Safeguarding the ipsilateral eye with artificial tears and lubricating ointments throughout nocturnal hours.
The topic of surgical decompression remains contentious.
CONTINUOUS CARE
• Crucial for ocular health and mental well-being.
COMPLICATIONS
• Incomplete healing in one-third of patients • Keratitis and corneal abrasions
Recurrence has been noted in 7–15% of instances.
BASICS DESCRIPTION
• Bell’s palsy is characterized by acute, idiopathic, unilateral paralysis of the facial nerve. • Approximately fifty percent of facial nerve palsy cases are classified as “Bell’s palsy.”
Bilateral illness constitutes a rare subtype, accounting for 0.3%.
ETIOLOGY
• Herpes simplex virus • Herpes zoster virus, including herpes zoster oticus • Negative occurrence after to vaccination
Epidemiology
Incidence • Rates range from 13 to 34 instances per 100,000 in the United States. • Incidence peaks among individuals aged 20–35 years and those over 70 years.
• The distribution of boys and females is equal. • Bell's palsy is the predominant etiology of VII nerve palsy in pediatric patients.
RISK FACTORS
• Gestation • Diabetes mellitus • Hypertension in individuals over 40 years
GENERAL PREVENTION
Currently, there is no method to avert Bell's palsy.
DIAGNOSIS
• Sudden onset within one to two days, fast advancement of partial or complete unilateral facial nerve paralysis • Reduced tear and saliva secretion on the affected side • Hyperacusis • Dysgeusia • Retroauricular pain
DIFFERENTIAL DIAGNOSIS
The differential diagnoses list is extensive and includes, among others:
• Echovirus and enterovirus infections • Lyme disease • HIV infection, onset during seroconversion • Otitis media and mastoiditis • Mycobacterium tuberculosis • Syphilis • Infectious meningitis • Rubella • Tetanus • Mycoplasma • Cholesteatoma • Sarcoidosis
• Sjögren’s syndrome • Systemic lupus erythematosus • Melkersson–Rosenthal syndrome • Cerebral aneurysm • Tumor of the parotid gland • Melanoma of the head and neck • Meningioma • Carcinomatous meningitis • Granulomatous meningitis of unknown cause • Guillain-Barré syndrome • Pseudobulbar palsy • Birth trauma • Petrous bone fractures • Iatrogenic/surgical complications
• Paget's disease
• Consider bilateral facial nerve paralysis in the context of:
– Lyme disease – Sarcoidosis
DIAGNOSTIC TESTS & INTERPRETATION
Laboratory
• Electrodiagnostic examinations:
Patients with an incomplete, typical lesion who recover do not require additional investigation. - Electromyography (EMG)
Electroneurography (also known as evoked electromyography)
Imaging
Imaging is required if the clinical presentation is abnormal, development is gradual, or there is no improvement after six months. A CT or MRI scan may be necessary to exclude intracerebral pathology or middle ear disease in complex cases. Recent studies indicate that the ultrasonography diameter of the distal VII nerve is a reliable prognostic indicator for Bell's palsy at three months post-onset.
THERAPY
Early administration of prednisolone markedly enhances the likelihood of full recovery at 3 and 9 months (Recommendation Grade 1A).
Treatment must commence within three days.
The advised dosage is 60–80 mg each day for one week.
• Antivirals are designated for severe facial palsy (Recommendation Grade 2C).
• Safeguarding the ipsilateral eye with artificial tears and lubricating ointments throughout nocturnal hours.
The topic of surgical decompression remains contentious.
CONTINUOUS CARE
• Crucial for ocular health and mental well-being.
COMPLICATIONS
• Incomplete healing in one-third of patients • Keratitis and corneal abrasions
Recurrence has been noted in 7–15% of instances.
- Published on
Infectious Disease -Bartonellosis (Oroya Fever/Verruga Peruana)
A disease caused by Bartonella bacilliformis, transmitted by the Phlebotomus sandfly, occurring in endemic regions in two distinct manifestations:
• Nonimmune individuals exhibit an acute febrile sickness accompanied by severe anemia (Oroya fever). • Following a variable duration post-resolution, a persistent, benign cutaneous manifestation may arise, marked by angioproliferative skin lesions (verruga peruana). The former exhibit a notable resemblance to lesions of bacillary angiomatosis, induced by Bartonella henselae and Bartonella quintana.
EPIDEMIOLOGY
Frequency
The disease is only confined to the valleys of the Andes River at elevations ranging from 600 to 2,500 meters in Peru, Ecuador, and Colombia.
• The majority of Oroya fever cases arise in tourists or visitors who
are immunologically inexperienced. The majority of verruga peruana cases occur within the indigenous community, with infrequent instances identified in the United States.
RISK FACTORS
Life in endemic regions and exposure to the sandfly vector GENERAL PREVENTION
Prevention necessitates the regulation of the sandfly vector: Application of dichlorodiphenyltrichloroethane (DDT) on both the interiors and exteriors of residences, utilization of insect repellents, and implementation of bed netting.
PATHOPHYSIOLOGY • Bartonella spp. infiltrate erythrocytes and endothelial cells. • They proliferate within intracellular vacuoles in the erythrocytes. The latter are subsequently engulfed and eliminated by the reticuloendothelial system.
ETIOLOGY • B. bacilliformis is a diminutive, gram-negative bacillus belonging to the class Proteobacteria, closely associated with B. quintana.
• It is spread through an arthropod vector, specifically the sandfly (Phlebotomus).
DIAGNOSTIC HISTORY
The incubation period for Oroya fever is approximately 3 weeks, with a maximum duration of 100 days.
The development of symptoms, primarily due to elevated temperature and severe anemia, may be either acute or subacute.
• Infectious problems arise from temporary immunosuppression.
The acute phase is followed by the convalescent period.
• Verruca skin lesions (nodules) manifest in clusters during a period of 1 to 2 months, after a variable interval after the remission of Oroya fever.
Acute manifestation (Oroya Fever)
• Subacute presentation (mild fever, malaise, cephalalgia, anorexia).
• Abrupt onset (elevated temperature, chills, sweating, cephalalgia, and alterations in cognitive function, succeeded by the rapid emergence of severe anemia).
• Myalgia and arthralgia.
• Dyspnea and angina; the patient may get the sensation that
The heart pulse is conveyed to the head and ears. • Anasarca serves as an indicator of unfavorable prognosis.
• Insomnia, delirium, diminished awareness, coma.
• In the ensuing convalescent (critical) phase, fever abates and anemia symptoms ameliorate.
PHYSICAL EXAMINATION
Oroya Fever • Elevated temperature • Indicators of severe anemia
• Generalized, nontender lymphadenopathy • Splenomegaly is uncommon; if observed, it may suggest an additional concomitant infection
• Thrombocytopenic purpura
Peruvian Wart
Miliary lesions comprise many papular, erythematous, round lesions measuring 1–4 mm, often accompanied by pruritus (1).
Nodular lesions, typically located on the skin and subcutaneous tissues of exposed body areas, may also involve mucous membranes and interior organs.
Mular lesions generally exceed 5 mm in diameter.
Characterized by erythema and a propensity to hemorrhage quickly.
• Lesions at different stages of development may be simultaneously present.
• Local tenderness is absent unless the patient has a secondary infection.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
In the acute phase, diagnosis is established through a positive culture (blood or bone marrow) or the identification of many organisms attached to red blood cells in peripheral thin-film blood smears (utilizing Giemsa or Wright stain). The bacterial count decreases sharply during convalescence.
Peripheral blood smears may reveal macrocytosis, poikilocytosis, Howell–Jolly bodies, nucleated red blood cells, and immature myeloid cells. The leukocyte differential exhibits a leftward shift, but the total count may remain within normal limits.
• Severe anemia; negative Coombs' test
In the subacute form, initial peripheral blood smears may yield negative results; diagnosis can be established through positive blood cultures.
Diagnosis of the chronic type can be achieved through the identification of the causal agent in culture.
Samples from cutaneous lesions and bone marrow cultures. • Blood cultures may yield positive results in asymptomatic patients. • Serological assays (ELISA, indirect fluorescent antibody, western immunoblot) can assist in diagnosis (2,3).
Pathological Findings: Skin biopsy, bone marrow aspiration, and biopsy specimens from further afflicted organs are utilized.
Enhanced angiogenesis, Rocha-Lima inclusions within endothelial cells
The polymerase chain reaction (PCR) for the detection of B. bacilliformis is currently in development.
DIFFERENTIAL DIAGNOSIS
• The acute phase can be readily distinguished from other endemic febrile conditions (e.g., malaria, typhoid fever, leptospirosis) through the analysis of peripheral blood smears and bacterial cultures. • Verruga peruana lesions bear resemblance to those of bacillary angiomatosis, Kaposi’s sarcoma, lymphoproliferative disorders, and other neoplasms. The primary diagnostic indicator is epidemiology.
THERAPEUTIC PHARMACEUTICAL
Oroya fever: Administer chloramphenicol (500 mg orally or intravenously every 6 hours) in conjunction with a secondary antibiotic, preferably a beta-lactam (such as penicillin), for a duration of 14 days (AII) (4).
Chloramphenicol is effective against salmonellosis, the prevalent secondary infection. The suggestion to incorporate a beta-lactam stems from the understanding that chloramphenicol alone is not dependable.
• Verruga peruana: – Administer Rifampin at a dosage of 10 mg/kg daily, not exceeding 600 mg daily, for a duration of 10–14 days (AII) orally (4). Second Line • Oroya fever: – Administer Doxycycline 100 mg orally twice daily for 14 days
The bacteria exhibits a prevalent resistance to ciprofloxacin.
Consequently, quinolones are not advised. • Verruga peruana: – Administer streptomycin at a dosage of 15–20 mg/kg intramuscularly on a daily basis for a duration of 10 days (AII)
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Supportive and symptomatic treatment is essential in the acute form; employ blood transfusion to ameliorate anemia.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
Extensive and secondarily infected cutaneous nodules may require surgical removal.
INPATIENT CONSIDERATIONS
Criteria for Admission
The suitable health care environment is inpatient for acute conditions and outpatient for chronic conditions.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
• Assess hydration levels and perform a complete blood count during the acute phase.
Monitor indicators of further infections: Splenomegaly, recurrent fever accompanied by leukocytosis throughout the convalescent phase, and diarrhea.
Observe verruca lesions for indications of subsequent infections.
PROGNOSIS • Untreated Oroya fever may result in mortality rates of 50–88%.
• Fever resolves within 24 hours following suitable antibiotic therapy, however bacteremia may endure for extended durations.
COMPLICATIONS
• Verruca lesions exhibit a varied response to antimicrobial therapy.
• Secondary bacterial infections, such as salmonellosis and other intestinal infections, malaria, and tuberculosis, are prevalent (45%) during the convalescent phase of Oroya fever. • Verruga lesions may become secondarily infected, leading to pustulation, ulceration, and hemorrhage.
A disease caused by Bartonella bacilliformis, transmitted by the Phlebotomus sandfly, occurring in endemic regions in two distinct manifestations:
• Nonimmune individuals exhibit an acute febrile sickness accompanied by severe anemia (Oroya fever). • Following a variable duration post-resolution, a persistent, benign cutaneous manifestation may arise, marked by angioproliferative skin lesions (verruga peruana). The former exhibit a notable resemblance to lesions of bacillary angiomatosis, induced by Bartonella henselae and Bartonella quintana.
EPIDEMIOLOGY
Frequency
The disease is only confined to the valleys of the Andes River at elevations ranging from 600 to 2,500 meters in Peru, Ecuador, and Colombia.
• The majority of Oroya fever cases arise in tourists or visitors who
are immunologically inexperienced. The majority of verruga peruana cases occur within the indigenous community, with infrequent instances identified in the United States.
RISK FACTORS
Life in endemic regions and exposure to the sandfly vector GENERAL PREVENTION
Prevention necessitates the regulation of the sandfly vector: Application of dichlorodiphenyltrichloroethane (DDT) on both the interiors and exteriors of residences, utilization of insect repellents, and implementation of bed netting.
PATHOPHYSIOLOGY • Bartonella spp. infiltrate erythrocytes and endothelial cells. • They proliferate within intracellular vacuoles in the erythrocytes. The latter are subsequently engulfed and eliminated by the reticuloendothelial system.
ETIOLOGY • B. bacilliformis is a diminutive, gram-negative bacillus belonging to the class Proteobacteria, closely associated with B. quintana.
• It is spread through an arthropod vector, specifically the sandfly (Phlebotomus).
DIAGNOSTIC HISTORY
The incubation period for Oroya fever is approximately 3 weeks, with a maximum duration of 100 days.
The development of symptoms, primarily due to elevated temperature and severe anemia, may be either acute or subacute.
• Infectious problems arise from temporary immunosuppression.
The acute phase is followed by the convalescent period.
• Verruca skin lesions (nodules) manifest in clusters during a period of 1 to 2 months, after a variable interval after the remission of Oroya fever.
Acute manifestation (Oroya Fever)
• Subacute presentation (mild fever, malaise, cephalalgia, anorexia).
• Abrupt onset (elevated temperature, chills, sweating, cephalalgia, and alterations in cognitive function, succeeded by the rapid emergence of severe anemia).
• Myalgia and arthralgia.
• Dyspnea and angina; the patient may get the sensation that
The heart pulse is conveyed to the head and ears. • Anasarca serves as an indicator of unfavorable prognosis.
• Insomnia, delirium, diminished awareness, coma.
• In the ensuing convalescent (critical) phase, fever abates and anemia symptoms ameliorate.
PHYSICAL EXAMINATION
Oroya Fever • Elevated temperature • Indicators of severe anemia
• Generalized, nontender lymphadenopathy • Splenomegaly is uncommon; if observed, it may suggest an additional concomitant infection
• Thrombocytopenic purpura
Peruvian Wart
Miliary lesions comprise many papular, erythematous, round lesions measuring 1–4 mm, often accompanied by pruritus (1).
Nodular lesions, typically located on the skin and subcutaneous tissues of exposed body areas, may also involve mucous membranes and interior organs.
Mular lesions generally exceed 5 mm in diameter.
Characterized by erythema and a propensity to hemorrhage quickly.
• Lesions at different stages of development may be simultaneously present.
• Local tenderness is absent unless the patient has a secondary infection.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
In the acute phase, diagnosis is established through a positive culture (blood or bone marrow) or the identification of many organisms attached to red blood cells in peripheral thin-film blood smears (utilizing Giemsa or Wright stain). The bacterial count decreases sharply during convalescence.
Peripheral blood smears may reveal macrocytosis, poikilocytosis, Howell–Jolly bodies, nucleated red blood cells, and immature myeloid cells. The leukocyte differential exhibits a leftward shift, but the total count may remain within normal limits.
• Severe anemia; negative Coombs' test
In the subacute form, initial peripheral blood smears may yield negative results; diagnosis can be established through positive blood cultures.
Diagnosis of the chronic type can be achieved through the identification of the causal agent in culture.
Samples from cutaneous lesions and bone marrow cultures. • Blood cultures may yield positive results in asymptomatic patients. • Serological assays (ELISA, indirect fluorescent antibody, western immunoblot) can assist in diagnosis (2,3).
Pathological Findings: Skin biopsy, bone marrow aspiration, and biopsy specimens from further afflicted organs are utilized.
Enhanced angiogenesis, Rocha-Lima inclusions within endothelial cells
The polymerase chain reaction (PCR) for the detection of B. bacilliformis is currently in development.
DIFFERENTIAL DIAGNOSIS
• The acute phase can be readily distinguished from other endemic febrile conditions (e.g., malaria, typhoid fever, leptospirosis) through the analysis of peripheral blood smears and bacterial cultures. • Verruga peruana lesions bear resemblance to those of bacillary angiomatosis, Kaposi’s sarcoma, lymphoproliferative disorders, and other neoplasms. The primary diagnostic indicator is epidemiology.
THERAPEUTIC PHARMACEUTICAL
Oroya fever: Administer chloramphenicol (500 mg orally or intravenously every 6 hours) in conjunction with a secondary antibiotic, preferably a beta-lactam (such as penicillin), for a duration of 14 days (AII) (4).
Chloramphenicol is effective against salmonellosis, the prevalent secondary infection. The suggestion to incorporate a beta-lactam stems from the understanding that chloramphenicol alone is not dependable.
• Verruga peruana: – Administer Rifampin at a dosage of 10 mg/kg daily, not exceeding 600 mg daily, for a duration of 10–14 days (AII) orally (4). Second Line • Oroya fever: – Administer Doxycycline 100 mg orally twice daily for 14 days
The bacteria exhibits a prevalent resistance to ciprofloxacin.
Consequently, quinolones are not advised. • Verruga peruana: – Administer streptomycin at a dosage of 15–20 mg/kg intramuscularly on a daily basis for a duration of 10 days (AII)
SUPPLEMENTARY THERAPY
Comprehensive Strategies
Supportive and symptomatic treatment is essential in the acute form; employ blood transfusion to ameliorate anemia.
OPERATIVE INTERVENTIONS/ADDITIONAL PROCEDURES
Extensive and secondarily infected cutaneous nodules may require surgical removal.
INPATIENT CONSIDERATIONS
Criteria for Admission
The suitable health care environment is inpatient for acute conditions and outpatient for chronic conditions.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
• Assess hydration levels and perform a complete blood count during the acute phase.
Monitor indicators of further infections: Splenomegaly, recurrent fever accompanied by leukocytosis throughout the convalescent phase, and diarrhea.
Observe verruca lesions for indications of subsequent infections.
PROGNOSIS • Untreated Oroya fever may result in mortality rates of 50–88%.
• Fever resolves within 24 hours following suitable antibiotic therapy, however bacteremia may endure for extended durations.
COMPLICATIONS
• Verruca lesions exhibit a varied response to antimicrobial therapy.
• Secondary bacterial infections, such as salmonellosis and other intestinal infections, malaria, and tuberculosis, are prevalent (45%) during the convalescent phase of Oroya fever. • Verruga lesions may become secondarily infected, leading to pustulation, ulceration, and hemorrhage.
- Published on
Balanitis
FUNDAMENTAL DESCRIPTION
Inflammation and/or infection of the glans penis. Balanoposthitis encompasses inflammation of the prepuce. This chapter will examine the infectious etiologies.
Epidemiology
Frequency
• Sexual exposure; heightened prevalence in men with female partners suffering from Candida vaginitis. • Balanitis in young boys frequently occurs alongside diaper dermatitis.
RISK FACTORS • Men who are uncircumcised
• Diabetes, particularly new-onset diabetes • For Candida, both colonization and infection age serve as independent risk factors
• Comprehensive-spectrum antibiotics
• Immunodeficiency • Inadequate hygiene
GENERAL PREVENTION • Circumcision • Proper hygiene • Treatment of sexual partner(s) diagnosed with Candida vaginitis or Trichomonas CAUSES
The pathogens implicated in infectious balanitis include, among others:
• Candida species • Trichomonas species • Anaerobic bacteria/Bacteroides species/Gardnerella vaginalis • Chlamydia • Neisseria gonorrhoeae • Human papillomavirus (HPV) • Herpes simplex virus (HSV) • Treponema pallidum
• Mycoplasma • Mycobacterium [Bacillus Calmette–Guerin (BCG)]
• Streptococcus (groups A and B) • Staphylococcus aureus
Borrelia burgdorferi (Lyme illness) • Entamoeba histolytica
DIAGNOSIS • Pain and soreness • Erosions • Erythema • Pruritus • Pustules • Foul odor of the glans penis associated with anaerobic infections • Swelling
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Fungal preparations typically signify Candida.
• A recent study demonstrated that direct impression on CHROMagar Candida medium as a sampling technique yielded a higher quantity of Candida spp than swabs.
• A wet mount may reveal Trichomonas.
• Wet mount preparation for Gardnerella.
• Evaluate the urethral discharge for sexually transmitted infections.
• Titers or cultures to detect HIV, HPV, and HSV. • Glucose assessment to exclude diabetes mellitus.
DIFFERENTIAL DIAGNOSIS • Noninfectious etiologies of balanitis - Irritants, including soaps
– Inadequate hygiene – Trauma – Contact dermatitis – Circinate balanitis – Lichen sclerosus – Lichen planus – Zoon's balanitis – Erythroplasia of Queyrat – Pemphigus – Pemphigoid – Bowen's illness
– Leukoplakia – Fixed drug eruption – Psoriasis, especially inverse psoriasis – Paget’s illness – Nummular eczema – Scabies – Squamous cell carcinoma
ADDITIONAL TREATMENT
Comprehensive Strategies
• Maintain proper hygiene by retracting the foreskin and gently cleansing the glans penis.
Local treatment for Candida balanitis involves the application of topical imidazoles. 1% hydrocortisone cream may serve as an adjunctive treatment.
• Administer oral fluconazole for severe Candida balanitis. • Trichomonas is susceptible to metronidazole.
• Concurrently treat sexual partner(s) for Candida or Trichomonas.
• Manage anaerobic infections with oral metronidazole, oral amoxicillin/clavulanate, or topical clindamycin cream.
CONTINUING TREATMENT POST-CARE SUGGESTIONS
Patients require monitoring by a physician for signs of recurrence or the onset of diabetes.
COMPLICATIONS
• Phimosis • Paraphimosis • Preputial fissure • Scarring
FUNDAMENTAL DESCRIPTION
Inflammation and/or infection of the glans penis. Balanoposthitis encompasses inflammation of the prepuce. This chapter will examine the infectious etiologies.
Epidemiology
Frequency
• Sexual exposure; heightened prevalence in men with female partners suffering from Candida vaginitis. • Balanitis in young boys frequently occurs alongside diaper dermatitis.
RISK FACTORS • Men who are uncircumcised
• Diabetes, particularly new-onset diabetes • For Candida, both colonization and infection age serve as independent risk factors
• Comprehensive-spectrum antibiotics
• Immunodeficiency • Inadequate hygiene
GENERAL PREVENTION • Circumcision • Proper hygiene • Treatment of sexual partner(s) diagnosed with Candida vaginitis or Trichomonas CAUSES
The pathogens implicated in infectious balanitis include, among others:
• Candida species • Trichomonas species • Anaerobic bacteria/Bacteroides species/Gardnerella vaginalis • Chlamydia • Neisseria gonorrhoeae • Human papillomavirus (HPV) • Herpes simplex virus (HSV) • Treponema pallidum
• Mycoplasma • Mycobacterium [Bacillus Calmette–Guerin (BCG)]
• Streptococcus (groups A and B) • Staphylococcus aureus
Borrelia burgdorferi (Lyme illness) • Entamoeba histolytica
DIAGNOSIS • Pain and soreness • Erosions • Erythema • Pruritus • Pustules • Foul odor of the glans penis associated with anaerobic infections • Swelling
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Fungal preparations typically signify Candida.
• A recent study demonstrated that direct impression on CHROMagar Candida medium as a sampling technique yielded a higher quantity of Candida spp than swabs.
• A wet mount may reveal Trichomonas.
• Wet mount preparation for Gardnerella.
• Evaluate the urethral discharge for sexually transmitted infections.
• Titers or cultures to detect HIV, HPV, and HSV. • Glucose assessment to exclude diabetes mellitus.
DIFFERENTIAL DIAGNOSIS • Noninfectious etiologies of balanitis - Irritants, including soaps
– Inadequate hygiene – Trauma – Contact dermatitis – Circinate balanitis – Lichen sclerosus – Lichen planus – Zoon's balanitis – Erythroplasia of Queyrat – Pemphigus – Pemphigoid – Bowen's illness
– Leukoplakia – Fixed drug eruption – Psoriasis, especially inverse psoriasis – Paget’s illness – Nummular eczema – Scabies – Squamous cell carcinoma
ADDITIONAL TREATMENT
Comprehensive Strategies
• Maintain proper hygiene by retracting the foreskin and gently cleansing the glans penis.
Local treatment for Candida balanitis involves the application of topical imidazoles. 1% hydrocortisone cream may serve as an adjunctive treatment.
• Administer oral fluconazole for severe Candida balanitis. • Trichomonas is susceptible to metronidazole.
• Concurrently treat sexual partner(s) for Candida or Trichomonas.
• Manage anaerobic infections with oral metronidazole, oral amoxicillin/clavulanate, or topical clindamycin cream.
CONTINUING TREATMENT POST-CARE SUGGESTIONS
Patients require monitoring by a physician for signs of recurrence or the onset of diabetes.
COMPLICATIONS
• Phimosis • Paraphimosis • Preputial fissure • Scarring
- Published on
Infectious Disease - Babesiosis
FUNDAMENTALS AND DESCRIPTION
Babesia is a protozoan that exhibits a preference for human erythrocytes. It is a prevalent etiology of hemolytic illness in endemic regions. The primary mode of transmission for Babesia microti is by bites from deer ticks (Ixodid species). Alternative, less prevalent transmission methods encompass blood transfusions and maternal transmission of babesiosis. The majority of B. microti is predominantly located in the Northeastern and Midwestern regions of the United States. Additional Babesia species are present in the western United States and Europe.
EPIDEMIOLOGY
• Babesia is classified as an emerging infectious illness due to the rising incidence of reported cases over the past decade. • The escalation of deer populations, tick density, and heightened human activity in endemic regions are believed to contribute to the increase in Babesia infections. • Numerous cases of Babesia remain subclinical in younger persons, suggesting that the incidence of this infection is likely underestimated. Data from blood donors indicate that 0.5–15% of individuals have been exposed in highly endemic regions.
FACTORS OF RISK
• Residing in or visiting endemic areas. • Patients without a spleen. • Immunosuppression (e.g., HIV, chemotherapy).
COMPREHENSIVE PREVENTION
• Individuals who are asplenic or immunocompromised, and so at heightened risk of severe illness, should avoid endemic locations during periods of elevated transmission, namely from May to October (3). Insect repellent is effective in preventing tick bites, particularly ones containing N-diethyl-meta-toluamide (DEET). Early removal of ticks is crucial; the tick must be attached for a minimum of 24 hours before transmission commences. Daily self-assessment is advised for individuals participating in outdoor activities in endemic regions. It is advisable to inspect pets for ticks in endemic regions. Clothing can be treated with permethrin to avert infection.
PATHOPHYSIOLOGY
The life cycle include the transmission of Babesia between vertebrate hosts and Ixodes ticks. Humans serve as "dead end" and "accidental" hosts, with the predominant transmission vectors for B. microti being white-footed mice and ticks. Humans may become unwell upon infection; yet, they do not contribute to the transmission of the pathogen. Ixodes ticks deliver sporozoites to the host's bloodstream. The sporozoites infiltrate the erythrocytes and transform into trophozoites. The trophozoites reproduce asexually through budding, resulting in 2–4 merozoites. The merozoites compromise red blood cells (RBCs) and infiltrate other RBCs, resulting in hemolysis and anemia. ETIOLOGY • The predominant cause of Babesia in the United States is B. microti, which is prevalent in New England, coastal New York, and the Midwest. Other prevalent Babesia species that induce sickness in humans are Babesia divergens in Europe and Babesia duncani in the Western United States.
FREQUENTLY CO-OCCURRING CONDITIONS
Co-infection with Lyme disease and human granulocytic anaplasmosis frequently occurs, as both are transmitted by Ixodes ticks in endemic areas. In endemic regions, up to 10% of those diagnosed with Lyme disease are concurrently infected with Babesia.
DIAGNOSIS HISTORY
Patients may be asymptomatic or exhibit the following symptoms: • Pyrexia • Rigors • Asthenia • Cephalalgia • Nausea/emesis • Abdominal discomfort • Diarrhea • Arthralgia • Dyspnea/thoracic pain • Darkened urine Inquire about recent Lyme disease illness, residence or travel in endemic regions, outdoor exposures, pet ownership, and recent tick bites.
PHYSICAL EXAMINATION
• Pyrexia • Splenomegaly • Hepatomegaly • Pallor • Icterus • Absence of lymphadenopathy • Assess for a rash indicative of erythema chronicum migrans in instances of Lyme co-infection
DIAGNOSTIC EXAMINATIONS & ANALYSIS
Laboratory Initial Assessments • Prepare thin blood smears to evaluate for intra-erythrocytic parasites and indications of hemolysis. In instances of low parasitemia and early infection, multiple blood smears may be required over several days. • Complete blood count: Anemia and thrombocytopenia detected. • Indicators of hemolysis: Increased reticulocyte count, LDH, and indirect bilirubin levels. Additionally, haptoglobin levels are low. • Hepatic function assays. Subsequent Actions & Unique Considerations • If the bacterium is undetected via blood smear, PCR amplification of 18S rRNA is advised. In patients with a significant likelihood of infection, indirect immunofluorescent antibody testing is advised when both blood smear and PCR results are negative. Imaging Imaging is typically unnecessary in moderate situations. Abdominal ultrasonography will verify hepatomegaly or splenomegaly. Pathological Observations Similar to malaria, Babesia manifests as an intra-erythrocytic parasite. Babesia parasites may be observed outside of red blood cells during severe infections, a phenomenon not present in malarial infections. At times, Babesia parasites (in the internal merozoite phase) manifest in tetrads, referred to as the "Maltese cross."
Differential Diagnosis: • Sepsis • Lyme Disease • Human Granulocytic Anaplasmosis • Hepatitis • Malaria • Lymphoma
TREATMENT MEDICATION
For B. microti infection: administer oral atovaquone 750 mg twice daily for 7–10 days, in conjunction with oral azithromycin 500–1,000 mg on day 1, followed by 250 mg daily thereafter. Second Line For B. microti infection: Administer oral quinine 650 mg three or four times daily in conjunction with oral clindamycin 600 mg three times daily for a duration of 7 to 10 days. Intravenous formulations are applicable. Quinine and clindamycin are utilized in critical instances.
SUPPLEMENTARY THERAPY
Comprehensive Strategies Asymptomatic immunocompetent people with detectable parasites on blood smear for less than three months do not necessitate treatment (5). Extended treatment durations may be required for immunocompromised individuals or in instances of significant parasite load. Treatment must persist for a minimum of 6 weeks, encompassing 2 weeks of therapy following the undetectability of parasites in blood smears. Concerns for Referral An infectious disease specialist should be consulted if there are indications of serious infection or infection in an immunocompromised individual. Supplementary Treatments Red blood cell exchange transfusions may be required in severe instances of excessive parasitemia (>10%) or the presence of shock/ARDS symptoms.
CONTINUING CARE FOLLOW-UP SUGGESTIONS
Patient Surveillance Hospitalized patients should undergo daily CBC and blood smear assessments to monitor for hemolysis, anemia, and parasite load.
INFORMATION FOR PATIENTS
Educate patients of the risk factors associated with Babesia transmission and implement measures to prevent re-infection.
COMPLICATIONS
• Disseminated Intravascular Coagulation (DIC) • Anemia • Congestive Heart Failure (CHF) • Acute Respiratory Distress Syndrome (ARDS) • Renal Dysfunction • Hypotension
FUNDAMENTALS AND DESCRIPTION
Babesia is a protozoan that exhibits a preference for human erythrocytes. It is a prevalent etiology of hemolytic illness in endemic regions. The primary mode of transmission for Babesia microti is by bites from deer ticks (Ixodid species). Alternative, less prevalent transmission methods encompass blood transfusions and maternal transmission of babesiosis. The majority of B. microti is predominantly located in the Northeastern and Midwestern regions of the United States. Additional Babesia species are present in the western United States and Europe.
EPIDEMIOLOGY
• Babesia is classified as an emerging infectious illness due to the rising incidence of reported cases over the past decade. • The escalation of deer populations, tick density, and heightened human activity in endemic regions are believed to contribute to the increase in Babesia infections. • Numerous cases of Babesia remain subclinical in younger persons, suggesting that the incidence of this infection is likely underestimated. Data from blood donors indicate that 0.5–15% of individuals have been exposed in highly endemic regions.
FACTORS OF RISK
• Residing in or visiting endemic areas. • Patients without a spleen. • Immunosuppression (e.g., HIV, chemotherapy).
COMPREHENSIVE PREVENTION
• Individuals who are asplenic or immunocompromised, and so at heightened risk of severe illness, should avoid endemic locations during periods of elevated transmission, namely from May to October (3). Insect repellent is effective in preventing tick bites, particularly ones containing N-diethyl-meta-toluamide (DEET). Early removal of ticks is crucial; the tick must be attached for a minimum of 24 hours before transmission commences. Daily self-assessment is advised for individuals participating in outdoor activities in endemic regions. It is advisable to inspect pets for ticks in endemic regions. Clothing can be treated with permethrin to avert infection.
PATHOPHYSIOLOGY
The life cycle include the transmission of Babesia between vertebrate hosts and Ixodes ticks. Humans serve as "dead end" and "accidental" hosts, with the predominant transmission vectors for B. microti being white-footed mice and ticks. Humans may become unwell upon infection; yet, they do not contribute to the transmission of the pathogen. Ixodes ticks deliver sporozoites to the host's bloodstream. The sporozoites infiltrate the erythrocytes and transform into trophozoites. The trophozoites reproduce asexually through budding, resulting in 2–4 merozoites. The merozoites compromise red blood cells (RBCs) and infiltrate other RBCs, resulting in hemolysis and anemia. ETIOLOGY • The predominant cause of Babesia in the United States is B. microti, which is prevalent in New England, coastal New York, and the Midwest. Other prevalent Babesia species that induce sickness in humans are Babesia divergens in Europe and Babesia duncani in the Western United States.
FREQUENTLY CO-OCCURRING CONDITIONS
Co-infection with Lyme disease and human granulocytic anaplasmosis frequently occurs, as both are transmitted by Ixodes ticks in endemic areas. In endemic regions, up to 10% of those diagnosed with Lyme disease are concurrently infected with Babesia.
DIAGNOSIS HISTORY
Patients may be asymptomatic or exhibit the following symptoms: • Pyrexia • Rigors • Asthenia • Cephalalgia • Nausea/emesis • Abdominal discomfort • Diarrhea • Arthralgia • Dyspnea/thoracic pain • Darkened urine Inquire about recent Lyme disease illness, residence or travel in endemic regions, outdoor exposures, pet ownership, and recent tick bites.
PHYSICAL EXAMINATION
• Pyrexia • Splenomegaly • Hepatomegaly • Pallor • Icterus • Absence of lymphadenopathy • Assess for a rash indicative of erythema chronicum migrans in instances of Lyme co-infection
DIAGNOSTIC EXAMINATIONS & ANALYSIS
Laboratory Initial Assessments • Prepare thin blood smears to evaluate for intra-erythrocytic parasites and indications of hemolysis. In instances of low parasitemia and early infection, multiple blood smears may be required over several days. • Complete blood count: Anemia and thrombocytopenia detected. • Indicators of hemolysis: Increased reticulocyte count, LDH, and indirect bilirubin levels. Additionally, haptoglobin levels are low. • Hepatic function assays. Subsequent Actions & Unique Considerations • If the bacterium is undetected via blood smear, PCR amplification of 18S rRNA is advised. In patients with a significant likelihood of infection, indirect immunofluorescent antibody testing is advised when both blood smear and PCR results are negative. Imaging Imaging is typically unnecessary in moderate situations. Abdominal ultrasonography will verify hepatomegaly or splenomegaly. Pathological Observations Similar to malaria, Babesia manifests as an intra-erythrocytic parasite. Babesia parasites may be observed outside of red blood cells during severe infections, a phenomenon not present in malarial infections. At times, Babesia parasites (in the internal merozoite phase) manifest in tetrads, referred to as the "Maltese cross."
Differential Diagnosis: • Sepsis • Lyme Disease • Human Granulocytic Anaplasmosis • Hepatitis • Malaria • Lymphoma
TREATMENT MEDICATION
For B. microti infection: administer oral atovaquone 750 mg twice daily for 7–10 days, in conjunction with oral azithromycin 500–1,000 mg on day 1, followed by 250 mg daily thereafter. Second Line For B. microti infection: Administer oral quinine 650 mg three or four times daily in conjunction with oral clindamycin 600 mg three times daily for a duration of 7 to 10 days. Intravenous formulations are applicable. Quinine and clindamycin are utilized in critical instances.
SUPPLEMENTARY THERAPY
Comprehensive Strategies Asymptomatic immunocompetent people with detectable parasites on blood smear for less than three months do not necessitate treatment (5). Extended treatment durations may be required for immunocompromised individuals or in instances of significant parasite load. Treatment must persist for a minimum of 6 weeks, encompassing 2 weeks of therapy following the undetectability of parasites in blood smears. Concerns for Referral An infectious disease specialist should be consulted if there are indications of serious infection or infection in an immunocompromised individual. Supplementary Treatments Red blood cell exchange transfusions may be required in severe instances of excessive parasitemia (>10%) or the presence of shock/ARDS symptoms.
CONTINUING CARE FOLLOW-UP SUGGESTIONS
Patient Surveillance Hospitalized patients should undergo daily CBC and blood smear assessments to monitor for hemolysis, anemia, and parasite load.
INFORMATION FOR PATIENTS
Educate patients of the risk factors associated with Babesia transmission and implement measures to prevent re-infection.
COMPLICATIONS
• Disseminated Intravascular Coagulation (DIC) • Anemia • Congestive Heart Failure (CHF) • Acute Respiratory Distress Syndrome (ARDS) • Renal Dysfunction • Hypotension
